Document:

Execution Version

 

INVESTMENT AGREEMENT

 

Dated
as of FEBRUARY 13, 2014

 

BY AND AMONG

 

DSS
Technology Management, INC., as the Company; and

 

DOCUMENT SECURITY SYSTEMS, INC. (for purposes
of Section 8.2.2 only); and

 

FORTRESS CREDIT CO LLC, as Collateral Agent;
and

 

THE INVESTORS FROM TIME TO TIME PARTY HERETO.

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	ARTICLE I DEFINITIONS	1
	 	1.1.	Certain Defined Terms	1
	 	1.2.	Other Interpretative Provisions	1
	 	 	 	 
	ARTICLE II TERMS OF THE ADVANCES	2
	 	2.1.	Initial Advance	2
	 	2.2.	First Milestone Advance	2
	 	2.3.	Second Milestone Advance	2
	 	2.3.	General Provisions	3
	 	3.3.	Taxes	3
	 	3.4.	Manner and Time of Payment	4
	 	3.4.	Patent License	4
	 	 	 	 
	ARTICLE III TERMS OF THE NOTES	4
	 	3.1.	Interest on the Notes	4
	 	3.2.	Maturity	5
	 	3.3.	Prepayments of the Notes	5
	 	 	 	 
	ARTICLE IV APPLICATION OF MONETIZATION PAYMENTS	5
	 	5.1.	Payment Waterfall	5
	 	 	 	 
	ARTICLE V CONDITIONS TO CLOSING	6
	 	5.1.	Conditions to Make the Initial Advance	6
	 	5.2.	Conditions to Make the First Milestone Advance	8
	 	5.3.	Conditions to Make the Second Milestone Advance	8
	 	 	 	 
	ARTICLE VI REPRESENTATIONS AND WARRANTIES	9
	 	6.1.	Organization and Business	9
	 	6.2.	Qualification	9
	 	6.3.	Operations in Conformity with Law, etc.	9
	 	6.4.	Authorization, Enforceability and Non-Contravention	9
	 	6.5.	Intellectual Property	10
	 	6.6.	Subsidiaries	10
	 	6.7.	Margin Regulations	10
	 	6.8.	Investment Company Act	10
	 	6.9.	Disclosure	11
	 	6.10.	Solvency	11
	 	6.11.	USA PATRIOT Act, FCPA and OFAC	11
	 	 	 	 
	ARTICLE VII COVENANTS	12
	 	7.1.	Taxes and Other Charges	12
	 	7.2.	Maintenance of Existence	13

 

    	-i-

    	 

    

 

	 	7.3.	Compliance with Legal Requirements	13
	 	7.4.	Notices; Certain Reports	13
	 	7.5.	Information Rights	14
	 	7.6.	Indebtedness	14
	 	7.7.	Liens	15
	 	7.8.	Management of Patents	15
	 	7.9.	Cash Collateral Account	15
	 	7.10.	Use of Proceeds	16
	 	7.11.	Further Assurances	16
	 	 	 	 
	ARTICLE VIII EVENTS OF DEFAULT	16
	 	8.1.	Events of Default	16
	 	8.2.	Certain Actions Following an Event of Default	18
	 	8.3.	Annulment of Defaults	21
	 	8.4.	Waivers	21
	 	 	 	 
	ARTICLE IX COLLATERAL AGENT	22
	 	9.1.	Appointment of Collateral Agent	22
	 	9.2.	Collateral	22
	 	9.3.	Collateral Agent’s Resignation	22
	 	9.4.	Concerning the Collateral Agent	22
	 	 	 	 
	ARTICLE X GENERAL PROVISIONS	24
	 	10.1.	Expenses	24
	 	10.2.	Indemnity	25
	 	10.3.	Notices	25
	 	10.4.	Amendments, Consents, Waivers, etc.	25
	 	10.5.	No Strict Construction	26
	 	10.6.	Certain Acknowledgments	26
	 	10.7.	Venue; Service of Process; Certain Waivers	26
	 	10.8.	WAIVER OF JURY TRIAL	27
	 	10.9.	Interpretation; Governing Law; etc.	27
	 	10.10.	Successors and Assigns	27
	 	10.11.	Tax Treatment	28
	 	10.12.	Confidentiality	30

 

    	-ii-

    	 

    

 

APPENDICES, SCHEDULES AND EXHIBITS

 

	Appendix I	 	Definitions
	Schedule I	 	Investors/Wire Instructions
	Schedule 2.1	 	Purchases at Initial Closing
	Schedule 2.2   	 	Purchases at First Milestone Advance
	Schedule 2.3	 	Purchases at Second Milestone Advance
	Schedule 5.1.1.5	 	Legal Counsel and Expert Consultants
	Schedule 6.5	 	Intellectual Property
	Schedule 6.6	 	Subsidiaries
	Schedule 7.8.1	 	Certain Patents
	Schedule 10.3	 	Notices
	Schedule I(a)	 	Certain Patents
	Schedule I(b)	 	Patents
	Schedule I(c)	 	Permitted Indebtedness
	Exhibit A	 	Assignment and Assumption Agreement
	Exhibit B	 	Patent Security Agreement
	Exhibit C	 	Patent License
	Exhibit D	 	Security Agreement
	Exhibit E	 	Initial Advance Note
	Exhibit F	 	First Milestone Note
	Exhibit G	 	Second Milestone Note

 

    	-iii-

    	 

    

 

INVESTMENT
AGREEMENT

 

This INVESTMENT AGREEMENT (this “Agreement”)
is dated as of February 13, 2014 by and among DSS Technology Management, Inc. a Delaware corporation (the “Company”),
Fortress Credit Co LLC as collateral agent (the “Collateral Agent”), each Person listed on Schedule I
attached hereto (collectively, together with their successors and assigns, the “Investors” and as variously noted on
Schedule I, the “Note Purchasers”, the “Fixed Return Interest Purchasers” and the
“Contingent Interest Purchasers”), and for purposes of Section 8.2.2 only, Document Security Systems,
Inc., a New York corporation (“DSS”).

 

RECITALS

 

WHEREAS, the Company has requested a series
of advances from the Investors, and, subject to the satisfaction of the conditions precedent set forth in Article V, the
Investors have agreed to purchase (x) upon the occurrence of the Initial Closing Date, the Contingent Interest and the Fixed Return
Interests and Notes set forth on Schedule 2.1 for an aggregate purchase price of $2,000,000 (collectively, the “Initial
Advance”), (y) upon the occurrence of the First Milestone Closing Date, the Notes and Fixed Return Interests set forth
on Schedule 2.2 for an aggregate purchase price of $1,000,000 (collectively, the “First Milestone Advance”)
and (z) upon the occurrence of the Second Milestone Closing Date, the Notes and Fixed Return Interests set forth on Schedule
2.3 for an aggregate purchase price of $1,500,000 (collectively, the “Second Milestone Advance”, and, together
with the Initial Advance and the First Milestone Advance, the “Advances”);

 

NOW THEREFORE, in consideration of the mutual
agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties agree as follows:

 

ARTICLE I

DEFINITIONS

 

1.1.        Certain
Defined Terms. Capitalized terms used in this Agreement and not otherwise defined shall have the meanings set forth in Appendix
I.

 

1.2.        Other
Interpretative Provisions. Unless otherwise specified, all references to “$”, “cash”, “dollars”
or similar references shall mean U.S. dollars, paid in cash or other immediately available funds. The definitions set forth in
this Agreement are equally applicable to both the singular and plural forms of the terms defined. The words “hereof”,
“herein”, and “hereunder” and words of like import when used in this Agreement
shall refer to this Agreement as a whole and not to any particular provision of this Agreement. All references to time of day herein
are references to New York, New York time (daylight or standard, as applicable) unless otherwise specifically provided. Where the
character or amount of any asset or liability or item of income or expense is required to be determined or any consolidation or
other accounting computation is required to be made for the purposes of this Agreement, it shall be done in accordance with GAAP
except where such principles are inconsistent with the specific provisions of this Agreement. References in this Agreement to an
Appendix, Exhibit, Schedule, Article, Section, clause or subclause refer (A) to the appropriate Appendix, Exhibit or Schedule to,
or Article, Section, clause or subclause in, this Agreement or (B) to the extent such references are not present in this Agreement,
to the Document in which such reference appears. The term “including” is by way of example and not limitation. The
word “or” is not exclusive. In the computation of periods of time from a specified date to a later specified date,
the word “from” means “from and including”; the words “to” and “until” each mean
“to but excluding”; and the word “through” means “to and including.” The term “documents”
includes any and all instruments, documents, agreements, certificates, notices, reports, financial statements and other writings,
however evidenced, whether in physical or electronic form. All references to any Person shall be constructed to include such Person’s
successors and assigns (subject to any restriction on assignment set forth herein). Unless otherwise expressly provided herein,
references to any law shall include all statutory and regulatory provisions consolidating, amending, replacing, supplementing or
interpreting such law.

 

    	 

    	 

    

 

ARTICLE II

TERMS OF THE ADVANCES

 

2.1.        Initial
Advance.

 

2.1.1.          Subject
to the terms and conditions of this Agreement (including Section 5.1), on the Initial Closing Date, the Company agrees to
issue and sell, and each Investor agrees to purchase, the Contingent Interest, the Notes and the Fixed Return Interests set forth
on Schedule 2.1 for the respective purchase prices set forth on Schedule 2.1. The purchase prices for the Contingent
Interest, the Fixed Return Interests and the Notes being purchased at the Initial Closing Date shall be payable in immediately
available funds by wire transfer to the deposit account of the Company as identified in writing by the Company to the Investors
prior to the Initial Closing Date.

 

2.2.        First
Milestone Advance.

 

2.2.1.          Subject
to the terms and conditions of this Agreement (including Section 5.2), on the First Milestone Closing Date, the Company
agrees to issue and sell, and each Investor agrees to purchase, the Notes and the Fixed Return Interests set forth on Schedule
2.2 for the respective purchase prices set forth on Schedule 2.2. The purchase prices for the Fixed Return Interests
and Notes being purchased at the First Milestone Closing Date shall be payable in immediately available funds by wire transfer
to the deposit account of the Company as identified in writing by the Company to the Investors prior to the First Milestone Closing
Date.

 

2.3.        Second
Milestone Advance.

 

2.3.1.          Subject
to the terms and conditions of this Agreement (including Section 5.3), on the Second Milestone Closing Date, the Company
agrees to issue and sell, and each Investor purchase, the Notes and the Fixed Return Interests set forth on Schedule 2.3
for the respective purchase prices set forth on Schedule 2.3. The purchase prices for the Fixed Return Interests and Notes
being purchased at the Second Milestone Closing Date shall be payable in immediately available funds by wire transfer to the deposit
account of the Company as identified in writing by the Company to the Investors prior to the Second Milestone Closing Date.

 

    	-2-

    	 

    

 

2.4.        General
Provisions.

 

2.4.1.          The
Company and each Investor agree that for federal and any applicable other tax jurisdiction, the purchase prices for the Contingent
Interest, the Notes and Fixed Return Interests shall be allocated as set forth on Schedules 2.1, 2.2 and 2.3
and that such allocations shall be used by the Company and each Investor for all financial and income tax reporting purposes.

 

2.4.2.          The
rights of the Investors under the Contingent Interest, the Fixed Return Interests and the Notes shall be secured pursuant to the
Collateral Documents, with the rights of the Contingent Interest Purchasers ranking junior in priority to the rights of the Note
Purchasers and the Fixed Return Interest Purchasers, and the rights of the Fixed Return Interest Purchasers ranking junior in priority
to the rights of the Note Purchasers.

 

2.4.3.          The
Company shall maintain a register of the Notes, Contingent Interest and Fixed Return Interests. For this limited purpose, the Company
shall be deemed an agent of the Investors.

 

2.4.4.          No
Investor shall be responsible for any default by any other Investor in its obligation to acquire its respective Pro Rata Share
of the Contingent Interest, Fixed Return Interests or Notes and each Investor shall be obligated to acquire the amounts to be purchased
by it hereunder, regardless of the failure of any other Investor to fulfill its obligations hereunder.

 

2.5.        Taxes.
Any and all payments by the Company hereunder shall be made free and clear of and without deduction for any and all present or
future taxes, levies, imposts, deductions, charges or withholdings in any such case imposed by the United States or any political
subdivision thereof, excluding taxes imposed or based on the recipient Investor’s overall net income, and franchise or capital
taxes imposed on it in lieu of net income taxes (all such non-excluded taxes, levies, imposts, deductions, charges, withholdings
and liabilities in respect of payments hereunder being hereinafter referred to as “Taxes”). If the Company shall
be required by law to deduct any Taxes from or in respect of any sum payable hereunder to any Investor, (i) the sum payable shall
be increased as may be reasonably necessary so that after making all required deductions for taxes (including deductions for taxes
applicable to additional sums payable under this Section 2.5) such Investor receives an amount equal to the sum it
would have received had no such deductions been made, (ii) the Company shall make such deductions and (iii) the Company shall remit
the full amount deducted to the relevant taxation authority or other authority in accordance with applicable law. Within 30 days
after the date of any payment of such Taxes, the Company shall furnish to the applicable Investor the original or certified copy
of a receipt evidencing payment thereof.

 

    	-3-

    	 

    

 

2.6.        Manner
and Time of Payment.

 

2.6.1.          All
payments to the Investors by the Company or the Collateral Agent under this Agreement shall be paid by wire transfer or other same
day funds to the Investors to their respective accounts designated on Schedule I (or such other account or address or the
attention of such other Person as the applicable Investor shall have specified by prior written notice to the Company and the Collateral
Agent).

 

2.6.2.          All
payments under this Agreement shall be made without defense, set off or counterclaim, in same day funds and delivered to the Investors
not later than 2:00 p.m. on the day such payment is due.

 

2.6.3.          All
payments made on the Notes, the Fixed Return Interests and the Contingent Interest, respectively, shall be made to the Investors
in accordance with their Pro Rata Share; provided, that principal payments on the Notes (together with any Make Whole Amounts applicable
thereto) shall be first applied to the Notes issued on the Initial Closing Date, second to any Notes issued on the First Milestone
Closing Date and third to any Notes issued on the Second Milestone Closing Date.

 

2.7.        Patent
License. The Company shall grant to the Collateral Agent, for the benefit of the Secured Parties, a non-exclusive, royalty-free,
license (including the right to grant sublicenses) with respect to the Patents, which shall be evidenced by, governed by, and reflected
in, the Patent License; provided, however, the Investors, the Collateral Agent and the Secured Parties agree that the Collateral
Agent shall not sublicense any of the “Licensed Patents” (as defined in the Patent License) until such time as an Event
of Default has occurred and is continuing (for the sake of clarity, after the expiration of any cure periods specified in Article
VIII); provided further that no sublicense granted by the Collateral Agent pursuant to the Patent License shall be revocable by
the Company, including on the basis that such Event of Default has been cured following the grant of such sublicense; provided
further that the Collateral Agent and Secured Parties agree to terminate the Patent License upon receipt of all amounts payable
to the Investors under Section 4.1. For the avoidance of doubt, the licenses granted to the Collateral Agent in the Patent License
are for the benefit of the Secured Parties only, and not the Collateral Agent, and the Collateral Agent shall not benefit from
or receive any direct or indirect compensation from or in connection with the Licensed Patents.

 

ARTICLE III

TERMS OF THE NOTES

 

3.1.        Interest
on the Notes.

 

3.1.1.          Interest
Rate. The Notes shall bear interest at a rate per annum equal to the Applicable Federal Rate on the unpaid principal amount
thereof (including any Capitalized Interest) from and including the applicable Closing Date until the principal amount (including
any Capitalized Interest) shall be paid in full in cash. Notwithstanding the foregoing, upon the occurrence of an Event of Default
and for so long as such Event of Default is continuing, the interest rate, to the extent permitted by law, on the unpaid principal
amount of the outstanding Notes shall increase to 2% per annum.

 

    	-4-

    	 

    

 

3.1.2.          Interest
Payments.

 

3.1.2.1.          Interest
on the aggregate outstanding amount of Notes shall be due and payable, in arrears, within 10 days following the end of each calendar
month (each such due date being an “Interest Payment Date”). On each Interest Payment Date, the Company will
pay interest on the Notes in cash, but if the Company does not make such a payment on the Interest Payment Date upon which it is
due, failure to pay such a payment will not constitute an Event of Default under this Agreement or a default under the Notes, and
such interest will automatically be capitalized and added to the principal amount of the Notes (the “Capitalized Interest”),
whereupon such Capitalized Interest shall be deemed additional principal of the Notes for all purposes hereunder.

 

3.1.3.          Interest
on the Notes shall be computed on the basis of a 360-day year and actual days elapsed. In computing such interest, the date or
dates of the making of the Notes shall be included and the date of payment shall be excluded.

 

3.2.          Maturity
The Notes shall mature on the Maturity Date, on which date the remaining unpaid amount of the then-outstanding Notes, together
with accrued and unpaid interest thereon and any Make Whole Amount with respect thereto, shall be immediately due and payable.

 

3.3.          Prepayments
of the Notes.

 

3.3.1.          Optional.
The Company may prepay in whole or in part (but, if in part, then in an amount that is an integral multiple of $500,000
and not less than $1,000,000) any Note at any time upon written notice delivered by the Company to the Note Purchasers no later
than 10:00 a.m. New York, New York time five (5) Business Days prior to the date of prepayment, such prepayment to be made
by the payment of (i) the principal amount to be prepaid, plus (ii) accrued interest thereon to the date fixed for prepayment
plus (iii) the Make Whole Amount applicable thereto.

 

3.3.2.          Mandatory.
The Company shall apply Monetization Payments to the prepayment of the Notes as required under Article IV. Any such prepayment
of the Notes shall be accompanied by the Make Whole Amount applicable thereto.

 

ARTICLE IV

APPLICATION OF MONETIZATION
PAYMENTS

 

4.1.          Payment
Waterfall. The Company shall apply the Monetization Payments to the payment of the Notes, the Fixed Return Interest, and the
Contingent Interest in the following order:

 

4.1.1.          100%
of the first $5,000,000 in Gross Receipts shall be paid (i) to the Note Purchasers until they have received payment in full of
the Notes (including accrued interest and any Make Whole Amount), then (ii) to the Fixed Return Interest Purchasers until they
have received the Fixed Return, and then (iii) to the Contingent Interest Purchasers until they have received the 2(x) Return.

 

    	-5-

    	 

    

 

4.1.2.          100%
of the next $3,300,000 in Gross Receipts may be retained by the Company or paid to counsel approved by the Majority Investors.

 

4.1.3.          The
Applicable Percentage of any Gross Receipts following the application of the first $8,300,000 as provided in Sections 4.1.1
and 4.1.2 shall be paid (i) to the Notes Purchasers until they have received payment in full of the Notes (including accrued
interest and any Make Whole Amount), then (ii) to the Fixed Return Interest Purchasers until they have received the Fixed Return,
and then (iii) to the Contingent Interest Purchasers until they have received the 2(x) Return.

 

4.2.          Contingent
Return.         After the Investors have received all amounts due under
Section 4.1, the Company shall pay the Contingent Interest Purchasers 12% of any remaining Gross Receipts and the Company
shall be entitled to the remaining 88% of such Gross Receipts. The Company or the Collateral Agent, as applicable, shall apply
any Gross Receipts as specified in this Section 4.2 not later than the 15th day following the end of the applicable
month, commencing with the calendar month in which the last payment required to be made under Section 4.1 is made.

 

ARTICLE V

CONDITIONS TO CLOSING

 

5.1.          Conditions
to Make the Initial Advance. The obligation of each Investor to advance its respective Pro Rata Share of the Initial Advance
on the Initial Closing Date is subject to the prior satisfaction of the conditions set forth in this Section 5.1:

 

5.1.1.     Delivery
of Documents. The Investors shall have received each of the following, each dated the Initial Closing Date except as set forth
below or as otherwise agreed by the Investors:

 

5.1.1.1.    this
Agreement;

 

5.1.1.2.    the
Security Agreement;

 

5.1.1.3.    the
Patent Security Agreement;

 

5.1.1.4.    the
Patent License;

 

5.1.1.5.    a
written consent signed by the Company which may be relied upon by its legal counsel and consultants, and in the case of legal counsel,
acknowledgements, in each case in form and substance satisfactory to the Investors, duly executed by each person set forth on Schedule
5.1.1.5;

 

5.1.1.6.    [reserved];

 

    	-6-

    	 

    

 

5.1.1.7.    (i) a
copy of the certificate or articles of incorporation, certification of formation or other constitutive document, including all
amendments thereto, of the Company, certified as of a recent date by the Secretary of State of the state of its organization and
a certificate as to the good standing of the Company as of a recent date, from such Secretary of State (or, in each case, a comparable
governmental official, if available); (ii) a certificate of the Secretary or Assistant Secretary of the Company dated the
Initial Closing Date and certifying (A) that attached thereto is a true and complete copy of the by-laws, or operating, limited
liability company, management or partnership agreement of the Company as in effect on the Initial Closing Date and at all times
since a date prior to the date of the resolutions described in clause (B) below, (B) that attached thereto is a true
and complete copy of resolutions duly adopted by the board of directors, sole manager or sole member, board of managers or members
of other governing body of the Company authorizing the execution, delivery and performance of the Documents, and that such resolutions
and consents have not been modified, rescinded or amended and are in full force and effect, (C) that the certificate or articles
of incorporation of the Company have not been amended since the date of the last amendment thereto shown on the certificate of
good standing furnished pursuant to clause (i) above, and (D) as to the incumbency and specimen signature of each officer
executing this Agreement or any other Document on behalf of the Company; and (iii) a certificate of another officer as to
the incumbency and specimen signature of the Secretary or Assistant Secretary executing the certificate pursuant to clause (ii)
above;

 

5.1.1.8.    a
customary opinion of counsel for the Company addressed to the Collateral Agent and the Investors, in form and substance reasonably
satisfactory to the Investors; and

 

5.1.1.9.    an
officer’s certificate from an Authorized Officer of the Company certifying that the conditions set forth in Sections 5.1.5
and 5.1.6 have been satisfied;

 

5.1.2.     Lien
Searches. The Investors shall have received copies of recent Uniform Commercial Code lien and judgment searches in each jurisdiction
reasonably requested by the Investors with respect to the Company.

 

5.1.3.     PATRIOT
Act Information. The Investors shall have received, at least five (5) days prior to the Initial Closing Date, all documentation
and other information about the Company requested by the Collateral Agent or the Investors under applicable “know your customer”
and anti-money laundering rules and regulations, including the PATRIOT Act.

 

5.1.4.     Fees
and Expenses. The Investors and the Collateral Agent shall have been paid their respective documented reasonable out-of-pocket
fees and expenses, including, to the extent invoiced on or prior to the Initial Closing Date, the fees and expenses of counsel
to the Investors, provided, however, in no event will the Company be required to pay more than seventy five thousand dollars ($75,000)
in the aggregate under this Section 5.1.4.

 

    	-7-

    	 

    

 

5.1.5.     Consents
and Approvals. No action, suit or proceeding (including, without limitation, any inquiry or investigation) shall be pending
or, to the knowledge of the Company, threatened against the Company. All necessary governmental and material third party approvals
and/or consents in connection with the transactions contemplated by this Agreement and otherwise referred to herein shall have
been obtained and remain in effect.

 

5.1.6.     Representations
and Warranties; No Default. The representations and warranties contained in this Agreement and the other Documents shall be
true and correct in all respects, and there shall exist no Default or Event of Default as of the applicable Closing Date, including
after giving effect to the advance of the Advances.

 

5.2.        Conditions
to Make the First Milestone Advance. The obligation of each Investor to advance its respective Pro Rata Share of the First
Milestone Advance on the First Milestone Closing Date is subject to the prior satisfaction of the conditions set forth in this
Section 5.2:

 

5.2.1.     Delivery
of a Milestone Notice. The Company shall furnish notice of the occurrence of the First Milestone to the Investors at least
ten (10) Business Days prior to the requested First Milestone Closing Date;

 

5.2.2.     Officer’s
Certificate. The Investors shall have received a certificate, dated the First Milestone Closing Date and signed by an Authorized
Officer of the Company, certifying that (x) the representations and warranties contained in this Agreement and the other Documents
are true and correct in all material respects as of the First Milestone Closing Date, except to the extent such representations
and warranties expressly relate to an earlier date, in which case they are true and correct in all material respects as of such
earlier date and except that any representation and warranty that is qualified as to “materiality,” “Material
Adverse Effect” or similar language is true and correct (after giving effect to any qualification therein) in all respects
and (y) there shall exist no Default or Event of Default as of the First Milestone Closing Date, including after giving effect
to the making of the First Milestone Advance; and

 

5.2.3.     Commitment
Expiration. The First Milestone Closing Date shall have occurred on or prior to the first anniversary of the Initial Closing
Date.

 

5.3.        Conditions
to Make the Second Milestone Advance. The obligation of each Investor to advance its respective Pro Rata Share of the Second
Milestone Advance on the Second Milestone Closing Date is subject to the prior satisfaction of the conditions set forth in this
Section 5.3:

 

5.3.1.     Delivery
of a Milestone Notice. The Company shall furnish notice of the occurrence of the Second Milestone to the Investors at least
ten (10) Business Days prior to the requested Second Milestone Closing Date;

 

    	-8-

    	 

    

 

5.3.2.     Officer’s
Certificate. The Investors shall have received a certificate, dated the Second Milestone Closing Date and signed by an Authorized
Officer of the Company, certifying that (x) the representations and warranties contained in this Agreement and the other Documents
are true and correct in all material respects as of the Second Milestone Closing Date, except to the extent such representations
and warranties expressly relate to an earlier date, in which case they are true and correct in all material respects as of such
earlier date and except that any representation and warranty that is qualified as to “materiality,” “Material
Adverse Effect” or similar language is true and correct (after giving effect to any qualification therein) in all respects
and (y) there shall exist no Default or Event of Default as of the Second Milestone Closing Date, including after giving effect
to the making of the Second Milestone Advance; and

 

5.3.3.     Commitment
Expiration. The Second Milestone Closing Date shall have occurred on or prior to the second anniversary of the Initial Closing
Date.

 

ARTICLE VI

REPRESENTATIONS AND
WARRANTIES

 

In order to induce each of the other parties
hereto to enter into this Agreement and the Investors to make the Advances, the Company hereby represents and warrants to the Investors
as follows, in each case, except as expressly stated, as of each Closing Date:

 

6.1.        Organization
and Business. The Company is (a) a duly organized and validly existing corporation or limited liability company, (b) in good
standing under the laws of the jurisdiction of its incorporation or organization and (c) has the power and authority, corporate
or otherwise, necessary (i) to enter into and perform this Agreement and the Documents to which it is a party and (ii) to carry
on the business now conducted or proposed to be conducted by it.

 

6.2.        Qualification.
The Company is duly and legally qualified to do business as a foreign corporation or limited liability company and is in good standing
in each state or jurisdiction in which such qualification is required and is duly authorized, qualified and licensed under all
laws, regulations, ordinances or orders of public authorities, or otherwise, to carry on its business in the places and in the
manner in which it is conducted.

 

6.3.        Operations
in Conformity with Law, etc. The operations of the Company as now conducted or proposed to be conducted are not in violation
of, nor is the Company in default under, any Legal Requirement.

 

6.4.        Authorization,
Enforceability and Non-Contravention. The Company has taken all corporate, limited liability or other action required to execute,
deliver and perform this Agreement and each other Document. This Agreement and each other Document constitutes the legal, valid
and binding obligation of the Company and is enforceable against the Company in accordance with their terms, except as enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally
and subject to general principles of equity and principles of good faith and fair dealing, regardless of whether considered in
a proceeding in equity or at law. All necessary consents, approvals and authorizations of any governmental or administrative agency
or any other Person of any of the transactions contemplated hereby shall been have been obtained and shall be in full force and
effect. This Agreement and each other Document does not (i) contravene the terms of any of the Company’s Organization Documents,
(ii) conflict with or result in any breach or contravention of, or the creation of any Lien under, or require any payment to be
made under (x) any Contractual Obligation of the Company or (y) any material order, injunction, writ or decree of any governmental
authority or any arbitral award to which the Company is subject or (iii) violate any Legal Requirement.

 

    	-9-

    	 

    

 

6.5.        Intellectual
Property. Except as otherwise set forth on Schedule 6.5 hereto, the Company is the entire, valid, sole and exclusive
owner of all right, title and interest to all of the Patents with good and marketable title free and clear of any and all Liens,
charges and encumbrances (other than Permitted Liens), including, without limitation, any and all pledges, assignments, licenses,
springing licenses, options, non-assertion agreements, earn-outs, monetization agreements, profit and revenue sharing arrangements,
derivative interests, fee and recovery splitting agreements, registered user agreements, shop rights and covenants by the Company
not to sue third persons, with the power to bring and sustain action and recover for past, present and future infringement without
having to join any other third party.  All recordings required to reflect record ownership of the Patents in the name of
the Company in the United Stated Patent & Trademark Office have been made. To the extent registered in the United Stated Patent
& Trademark Office, the Company listed as record owners of all of the Patents and the recordings in the IP Filings Offices
do not reflect any defects in chain-of-title or unreleased liens. All of the Patents are subsisting and have not been adjudged
invalid or unenforceable, in whole or in part, and, to the Company’s knowledge, none of the Patents are at this time the
subject to any challenge to their validity or enforceability. To the knowledge of the Company the Patents are, valid and enforceable.
The Company has received no notice of any lawsuits, actions or opposition, cancellation, revocation, re-examination or reissue
proceedings commenced or threatened with reference to any of the Patents.

 

6.6.        Subsidiaries.
The Company owns no Subsidiaries other than those listed on Schedule 6.6 hereto, and, excluding Liens on assets of the Company’s
Subsidiaries, all of the outstanding equity interests in the Company’s Subsidiaries have been validly issued, are fully paid
and are owned free and clear of all Liens. There are no outstanding commitments or other obligations of the Company to issue, and
no options, warrants, convertible securities or other rights of any Person to acquire, any shares of any class of capital stock
or other equity interests of the Company.

 

6.7.        Margin
Regulations. The Company is not engaged nor will it engage, principally or as one of its important activities, in the business
of purchasing or carrying Margin Stock, or extending credit for the purpose of purchasing or carrying Margin Stock, and the Advance
will not be used for any purpose that violates Regulation U of the Board of Governors of the United States Federal Reserve System.

 

6.8.        Investment
Company Act. The Company is not, nor is it required to be, registered as an “investment company” under the Investment
Company Act of 1940.

 

    	-10-

    	 

    

 

6.9.        Disclosure.
No report, financial statement, certificate or other written information furnished by or on behalf of the Company (other than projected
financial information and information of a general economic or industry nature) to the Collateral Agent or any Investor in connection
with the transactions contemplated hereby and the negotiation of this Agreement or delivered hereunder or any other Document (as
modified or supplemented by other information so furnished) when taken as a whole contains any material misstatement of fact or
omits to state any material fact necessary to make the statements therein (when taken as a whole), in the light of the circumstances
under which they were made, not materially misleading. With respect to projected financial information, the Company represents
that such information was prepared in good faith based upon assumptions believed to be reasonable at the time of preparation; it
being understood that such projections may vary from actual results and that such variances may be material.

 

6.10.      Solvency.
Both before and after giving effect to the Advances made on or prior to the date this representation and warranty is made or remade
and the payment and accrual of all transaction costs in connection with the foregoing, the Company is Solvent.

 

6.11.      USA
PATRIOT Act, FCPA and OFAC.

 

6.11.1.   To
the extent applicable, the Company is in compliance, in all material respects, with (i) the Trading with the Enemy Act, as amended,
and each of the foreign assets control regulations of the United States Treasury Department (31 CFR Subtitle B, Chapter V, as amended)
and any other enabling legislation or executive order relating thereto and (ii) the USA Patriot Act.

 

6.11.2.   No
part of the proceeds of the Advance will be used, directly or indirectly, for any payments to any governmental official or employee,
political party, official of a political party, candidate for political office, or anyone else acting in an official capacity,
in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt
Practices Act of 1977, as amended.

 

6.11.3.   The
Company is not and, to the knowledge of the Company, no director, officer, agent, employee or controlled Affiliate of the Company
is, currently the subject of any U.S. sanctions program administered by the Office of Foreign Assets Control of the United States
Department of the Treasury (“OFAC”); and the Company will not directly or indirectly knowingly use the proceeds
of the Advance or otherwise knowingly make available such proceeds to any Person, for the purpose of financing the activities of
any Person currently the subject of any U.S. sanctions program administered by OFAC, except to the extent licensed or otherwise
approved by OFAC.

 

In order to induce the Company to enter
into this Agreement, each Investor hereby represents and warrants to the Company as follows, in each case, except as expressly
stated, as of each Closing Date:

 

6.12.      Organization
and Business. Such Investor is (a) a duly organized and validly existing corporation or limited liability company, (b) in good
standing under the laws of the jurisdiction of its incorporation or organization and (c) has the power and authority, corporate
or otherwise, necessary to enter into and perform this Agreement and the Documents to which it is a party.

 

    	-11-

    	 

    

 

6.13.      Qualification.
Such Investor is duly and legally qualified to do business as a foreign corporation or limited liability company and is in good
standing in each state or jurisdiction in which such qualification is required, and is duly authorized, qualified and licensed
under all laws, regulations, ordinances or orders of public authorities, or otherwise, to carry on its business in the places and
in the manner in which it is conducted, in each case, to the extent material to its ability to enter into and perform this Agreement
and the Documents to which it is a party.

 

6.14.      Operations
in Conformity with Law, etc. The Investor’s entry into this Agreement and the performance of its obligations under this
Agreement and the Documents to which is it a party are not in violation of, nor constitute a default under, any Legal Requirement.

 

6.15.      Authorization,
Enforceability and Non-Contravention. Such Investor has taken all corporate, limited liability or other action required to
execute, deliver and perform this Agreement and each other Document to which it is a party. This Agreement and each other Document
to which Investor is a party constitutes the legal, valid and binding obligation of Investor and is enforceable against Investor
in accordance with their terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or
other laws affecting creditors’ rights generally and subject to general principles of equity and principles of good faith
and fair dealing, regardless of whether considered in a proceeding in equity or at law. All necessary consents, approvals and authorizations
of any governmental or administrative agency or any other Person for the Investors to enter into or perform of any of the transactions
contemplated hereby shall been have been obtained and shall be in full force and effect.

 

6.16.      Investor
Status. At the time such Investor was offered the Notes, Fixed Return Interests, or the Contingent Interests, it was, and as
of the date hereof it is, and on each date on which it makes any Advances, it will be an “accredited investor” as defined
in Rule 501 under the Securities Act of 1933, as amended.

 

ARTICLE VII

COVENANTS

 

The Company shall observe each of the covenants
set forth in this Article VII:

 

7.1.        Taxes
and Other Charges. The Company shall duly pay and discharge, or cause to be paid and discharged, before the same becomes in
arrears, all taxes, assessments and other governmental charges imposed upon such Person and its properties, sales or activities,
or upon the income or profits therefrom; provided, however, that any such tax, assessment, charge or claim need not
be paid if the validity or amount thereof shall at the time be contested in good faith by appropriate proceedings and if such Person
shall, in accordance with GAAP, have set aside on its books adequate reserves with respect thereto; and provided, further,
that the Company shall pay or bond, or cause to be paid or bonded, all such taxes, assessments, charges or other governmental claims
immediately upon the commencement of proceedings to foreclose any Lien which may have attached as security therefor (except to
the extent such proceedings have been dismissed or stayed).

 

    	-12-

    	 

    

 

7.2.        Maintenance
of Existence. The Company shall do all things necessary to preserve, renew and keep in full force and effect and in good standing
its legal existence and authority necessary to continue its business.

 

7.3.        Compliance
with Legal Requirements. The Company shall comply in all material respects with all valid Legal Requirements applicable to
it, except where compliance therewith shall at the time be contested in good faith by appropriate proceedings.

 

7.4.        Notices;
Certain Reports.

 

7.4.1.     Certain
Notices. The Company shall, promptly following it having notice or knowledge thereof, furnish to each of the Investors notice
of the following:

 

7.4.1.1.          any
dispute, litigation, investigation, suspension or any administrative or arbitration proceeding by or against the Company or affecting
the Company’s ownership rights with respect to the Patents;

 

7.4.1.2.          the
occurrence of the First Milestone and the Second Milestone; and

 

7.4.1.3.          promptly
upon acquiring knowledge thereof, the existence of any Default or Event of Default, specifying the nature thereof and what action
the Company has taken, is taking or proposes to take with respect thereto.

 

Each notice pursuant to this
Section shall be accompanied by a statement by an Authorized Officer of the Company, on behalf of the Company, setting forth
details of the occurrence referred to therein, and stating what action the Company or other Person proposes to take with respect
thereto and at what time. Each notice under Section 7.4.1.3 shall describe with particularity any and all clauses or
provisions of this Agreement or other Document that have been breached or violated.

 

7.4.2.     Certain
Reports. The Company shall furnish the following information to the Investors:

 

7.4.2.1.          no
later than the 15th day of every month, a report setting forth the Gross Receipts, together with detailed supporting
calculations, in form and substance reasonably satisfactory to the Majority Investors;

 

7.4.2.2.          promptly
(and in any event within five (5) Business Days) after execution thereof, copies of all judgments, settlement agreements or licenses
with respect to the Patents; and

 

7.4.2.3.          promptly
(and in any event within five (5) Business Days), such additional information relating to the Company’s Monetization Activities
or such additional business, financial, corporate affairs and other information as the Majority Investors may from time to time
reasonably request.

 

    	-13-

    	 

    

 

7.5.        Information
Rights.

 

7.5.1.     The
Company shall participate in quarterly conference calls with the Investors to discuss its Monetization Activities, and shall provide
such letters, filings or other materials as are reasonably necessary to describe the status of the Company’s Monetization
Activities or as otherwise reasonably requested by the Majority Investors prior to or following such call, provided that
the Company shall not be required to provide any materials to the extent that the provision of such materials to the Investors
would, in its reasonable judgment on the advice of counsel, jeopardize the Company’s entitlement to invoke any work-product
or other form of evidentiary privilege.

 

 

7.5.2.     Upon
three (3) Business Days prior request of the Majority Investors, the Company shall permit any Investor and any Investor’s
duly authorized representatives and agents to visit and inspect any of its property, corporate books, and financial records reasonably
related to the Monetization Activities and the other obligations of the Company under this Agreement, to examine and make copies
of its books of accounts and other financial records reasonably related to the Monetization Activities and the other obligations
of the Company under this Agreement, and to discuss its affairs, finances, and accounts reasonably related to the Monetization
Activities and the other obligations of the Company under this Agreement with, and to be advised as to the same by, its managers,
officers, employees and independent public accountants (and by this provision the Company hereby authorizes such accountants to
discuss with the Investors the finances and affairs of the Company so long as (i) an officer or manager of the Company has been
afforded a reasonable opportunity to be present for such discussion and (ii) such accountants shall be bound by standard confidentiality
obligations). In addition, upon prior request of the Majority Investors, the Company shall provide the Investors with a status
update of any material development in any litigations or any administrative or arbitration proceeding related to the Patents. All
reasonable costs and expenses incurred by the Investors and their duly authorized representatives and agents in connection with
the first time the Investors’ exercise their rights pursuant to this Section 7.5.2 in any fiscal year shall be paid
by the Company. All reasonable costs and expenses incurred by the Investors and their duly authorized representatives and agents
in connection with any subsequent exercise of the Investors’ pursuant to this Section 7.5.2 in such fiscal year shall
only be paid by the Company if the results of the Investors’ investigation show a shortfall in payments owed to the Investors
hereunder in excess of ten percent (10%).

 

7.6.        Indebtedness.
Until such time as the Investors have received payments under Article IV in an aggregate amount equal to the aggregate amount
of all Advances made by the Investors, the Company shall not create, incur, assume or otherwise become or remain liable with respect
to any Indebtedness (other than Permitted Indebtedness) unless (i) the Company shall have obtained the prior written consent of
the Majority Investors or (ii) at the Company’s expense, the Patents have been first transferred to a special purpose entity
in accordance with Section 8.2.1.3.

 

    	-14-

    	 

    

 

7.7.        Liens.
The Company shall not create, incur, assume or suffer to exist any Lien upon any Patent except for (i) Liens securing the Obligations
and (ii) non-exclusive licenses that are entered into pursuant to a Company’s Monetization Activities (such Liens, collectively,
“Permitted Liens”).

 

7.8.        Management
of Patents.

 

7.8.1.     Monetization
Activities. The Company shall undertake commercially reasonable efforts to pursue the monetization of the Patents; provided
that, without the prior written consent of the Majority Investors, the Company shall not pursue monetization of the Patents listed
on Schedule 7.8.1 until such time as the Investors have received payments under Article IV in an aggregate amount
equal to the aggregate amount of all Advances made by the Investors.

 

7.8.2.     Dispositions.
The Company shall not make any Disposition of any Patents (other than assignment to a special purpose entity as and when required
pursuant to this Agreement) without the prior written consent of the Majority Investors other than the entry into settlement agreements
or non-exclusive licensing arrangements with respect to the Patents in furtherance of Monetization Activities.

 

7.8.3.     Preservation
of Patents. The Company shall, at its own expense, take all reasonable steps to pursue the registration and maintenance of
each Patent and shall take all necessary steps to preserve and protect each Patent. The Company shall not do or permit any act
or knowingly omit to do any act whereby any of the Patents may lapse, be terminated, or become invalid or unenforceable or placed
in the public domain. At its option, the Collateral Agent or the Majority Investors may, at the Company’s expense, take all
reasonable steps to pursue the registration and maintenance of each Patent and to preserve and protect each Patent, and the Company
hereby grants the Collateral Agent a power-of-attorney to take all steps in the Company’s name in furtherance of the foregoing;
provided that the foregoing shall not be interpreted as excusing the Company from the performance of, or imposing any obligation
on the Collateral Agent or the Majority Investors to cure or perform any obligation of the Company.

 

7.8.4.     Entry
into Agreements. The Company shall not enter into any contract or other agreement with respect to the Patents that contains
confidentiality provisions prohibiting or otherwise restricting the Company from (x) disclosing the existence of such contract
or other agreement to the Investors and their counsel or (y) complying with its obligations under Section 7.5.

 

7.9.        Cash
Collateral Account. Within 30 days following the Initial Closing Date, the Company shall open a depository account (the “Cash
Collateral Account”) with a depository bank reasonably acceptable to the Collateral Agent, which Cash Collateral Account
shall be subject to a control agreement between the Company, such depository bank and the Collateral Agent, and shall be in form
and substance satisfactory to the Majority Investors. The Company shall cause all Monetization Payments to be deposited into such
Cash Collateral Account, and the Company hereby authorizes the Majority Investors to inform any payor of Monetization Payments
of the Company’s obligation to direct all Monetization Payments to the Cash Collateral Account as required hereunder. On
each deposit of Monetization Payments to the Cash Collateral Account, the Company shall deliver an officer’s certificate
to the Majority Investors setting forth the Company’s calculation of the required application of proceeds of such Monetization
Payments. The Cash Collateral Account shall be under the sole control of the Collateral Agent and the Company may not have access
to, or otherwise control, the Cash Collateral Account; provided that the Collateral Agent shall make withdrawals from the
Cash Collateral Account in order to pay amounts owed to the Collateral Agent or the Investors pursuant to Article III, Article
IV, Section 10.1 or Section 10.2; provided further that the balance in the Collateral Account following
such application shall be promptly distributed to the Company.

 

    	-15-

    	 

    

 

7.10.      Use
of Proceeds. The proceeds of the Advances shall be used to pursue Monetization Activities related to the Patents, to pay transaction
expenses related to the Agreement and for general corporate purposes.

 

7.11.      Further
Assurances. Upon the reasonable request of the Majority Investors or the Collateral Agent, the Company shall (i) correct any
material defect or error that may be discovered in the execution, acknowledgment, filing or recordation of any Document or other
document or instrument relating to any Collateral and (ii) do, execute, acknowledge, deliver, record, re-record, file, re-file,
register and re-register any and all such further acts, deeds, certificates, assurances and other instruments as the Collateral
Agent or Majority Investors may reasonably request from time to time in order to carry out the purposes of the Documents.

 

ARTICLE VIII

EVENTS OF DEFAULT

 

8.1.        Events
of Default. Each of the following events is referred to as an “Event of Default”:

 

8.1.1.     Payment.
The Company shall fail to make any payment due hereunder when such payment is due and payable.

 

8.1.2.     Fixed
Returns. On or prior to the second anniversary of the Initial Closing Date, the Investors shall fail to have received payments
from the Company in an amount equal to the aggregate amount of all Advances made by the Investors, or on or prior to the fourth
anniversary of the Initial Closing Date, the Investors shall fail to have received payments from the Company in an amount equal
to two times the aggregate amount of all Advances made by the Investors on or prior to the fourth anniversary of the Initial Closing
Date.

 

8.1.3.     Other
Covenants. (x) The Company shall fail to perform or observe any of the covenants or agreements contained in Section 7.2
and Section 7.5 through Section 7.10 or (y) the Company shall fail to perform or observe any of the covenants or
agreements in Article VII or elsewhere in this Agreement or in any other Document (other than those covenants or agreements
specified in clause (x) above) and such failure continues for thirty (30) days after the earlier of (i) the Company obtaining knowledge
of such failure and (ii) the Company’s receipt of notice of any such failure.

 

    	-16-

    	 

    

 

8.1.4.     Representations
and Warranties. Any representation or warranty of or with respect to any party, pursuant to or in connection with any Document,
or in any financial statement, report, notice, mortgage, assignment or certificate delivered by the party so representing to the
other parties hereto in connection herewith or therewith, shall be false in any material respect on the date as of which it was
made.

 

8.1.5.     Cross-Default.
Any default or event of default with respect to any Indebtedness in excess of $500,000 of the Company shall occur and be continuing.

 

8.1.6.     Ownership;
Liquidation; etc.

 

8.1.6.1.        
 A Change of Control shall have occurred.

 

8.1.6.2.      
   The Company shall initiate any action to dissolve, liquidate or otherwise terminate its existence.

 

8.1.7.     Enforceability,
etc. Any material provisions of any Document shall cease for any reason to be valid and binding on or enforceable against the
Company in accordance with its terms or in full force and effect; or the Company or any Affiliate thereof shall so assert in a
judicial or similar proceeding.

 

8.1.8.     Judgments.
A final judgment (a) which, with other outstanding final judgments against the Company, exceeds an aggregate of $500,000 shall
be rendered against the Company or (b) which grants injunctive relief that results, or creates a material risk of resulting, in
a Material Adverse Effect and in either case if (i) within 30 days after entry thereof (or such longer period permitted under
the terms of such judgment), such judgment shall not have been discharged or execution thereof stayed pending appeal or (ii) within
thirty (30) days after the expiration of any such stay, such judgment shall not have been discharged.

 

8.1.9.     Bankruptcy,
etc. The Company shall:

 

8.1.9.1.          commence
a voluntary case under the Bankruptcy Code or authorize, by appropriate proceedings of its board of directors or other governing
body, the commencement of such a voluntary case;

 

8.1.9.2.          (i)
have filed against it a petition commencing an involuntary case under the Bankruptcy Code that shall not have been dismissed within
60 days after the date on which such petition is filed or (ii) file an answer or other pleading within such 60-day period admitting
or failing to deny the material allegations of such a petition or seeking, consenting to or acquiescing in the relief therein provided
or (iii) have entered against it an order for relief in any involuntary case commenced under the Bankruptcy Code;

 

    	-17-

    	 

    

 

8.1.9.3.          seek
relief as a debtor under any applicable law, other than the Bankruptcy Code, of any jurisdiction relating to the liquidation or
reorganization of debtors or to the modification or alteration of the rights of creditors, or consent to or acquiesce in such relief;

 

8.1.9.4.          have
entered against it an order by a court of competent jurisdiction (i) finding it to be bankrupt or insolvent, (ii) ordering
or approving its liquidation or reorganization as a debtor or any modification or alteration of the rights of its creditors or
(iii) assuming custody of, or appointing a receiver or other custodian for, all or a substantial portion of its property; or

 

8.1.9.5.          make
an assignment for the benefit of, or enter into a composition with, its creditors, or appoint, or consent to the appointment of,
or suffer to exist a receiver or other custodian for, all or a substantial portion of its property.

 

8.1.10.   Collateral.
Any material provision of any Document shall for any reason cease to be valid and binding on or enforceable against the Company
or the Company shall so state in writing or bring an action to limit its obligations or liabilities thereunder; or any Collateral
Document shall for any reason (other than pursuant to the terms thereof) cease to create a valid security interest in the Collateral
purported to be covered thereby or such security interest shall for any reason (other than the failure of the Collateral Agent
to take any action within its control) cease to be a perfected and first priority security interest subject only to Permitted Liens.

 

8.2.        Certain
Actions Following an Event of Default.

 

8.2.1.     If
an Event of Default has occurred and is continuing, the Collateral Agent and the Investors shall have the remedies set forth below
(in addition to the right to seek specific performance of any covenant), which may be exercised through any appropriate proceeding;
provided that, except with respect to an Event of Default under Section 8.1.9, and except for any other Event
of Default that is not capable of being cured (in the reasonable judgment of the Majority Investors), the Collateral Agent and
the Investors shall refrain from exercising remedies and the Company shall have the further right to cure such Event of Default
for a period of three (3) Business Days after the Collateral Agent or the applicable Investors provides written notice to the Company
of their intent to exercise remedies on account of such Event of Default; and provided further, that other than in the case of
a Bankruptcy Default, prior to initiating litigation to effect a specified remedy, the Collateral Agent shall make a written request
on the Company to effect such remedy consensually and without litigation and to the extent the Company promptly complies, will
permit the Company to effect such remedy consensually:

 

8.2.1.1.          Foreclosure
on Collateral. The Majority Investors (or the Collateral Agent, acting at the direction of the Majority Investors) may foreclose
on the Collateral or exercise other remedies with respect to the Collateral as set forth under the Security Agreement.

 

    	-18-

    	 

    

 

8.2.1.2.          Direct
Monetization Activities. The Majority Investors (or the Collateral Agent, acting at the direction of the Majority Investors)
may direct the Company to take any action requested by the Majority Investors (or the Collateral Agent, acting at the direction
of the Majority Investors) in any Monetization Activity regarding the Patents.

 

8.2.1.3.          Special
Purpose Entity. The Majority Investors (or the Collateral Agent, acting at the direction of the Majority Investors) may direct
the Company to assign, at the Company’s expense, the Patents to a special purpose entity controlled solely by the Majority
Investors, subject to a perpetual, non-transferable, non-exclusive, worldwide, royalty-free license back to the Company (without
the right to sub-license) that permits the Company to use the Patents to sell their products and to comply with arrangements entered
into subsequent to the Initial Closing Date in compliance with this Agreement. In such event, the Company’s sole right and
interest in such special purpose entity shall be to retain any Monetization Payments (after payment of expenses of the entity,
including expenses in pursuing monetization activities related to the Patents) net of the payment obligations of the Company pursuant
to Articles III and IV and Sections 10.1 and 10.2, which shall be distributed, at the Company’s
expense, by the special purpose entity to the Collateral Agent or Investors in accordance with their Pro Rata Share, as applicable.

 

8.2.1.4.          Patent
License. The Collateral Agent may exercise its rights under the license granted by the Company pursuant to the Patent License,
subject to the terms and conditions of Section 2.7, until terminated pursuant to Section 2.7.

 

8.2.1.5.          Standstill.
Upon notice in writing from the Majority Investors (or the Collateral Agent, acting at the direction of the Majority Investors),
the Company shall not enter into any new pledges, assignments, licenses, springing licenses, options, non-assertion agreements,
earn-outs, monetization agreements, profit and revenue sharing arrangements, derivative interests, fee and recovery splitting agreements,
registered user agreements, shop rights and covenants by the Company not to sue third persons with respect to any of the Patents.

 

    	-19-

    	 

    

 

8.2.1.6.          Acceleration.
The Majority Investors (or the Collateral Agent, acting at the direction of the Majority Investors), may, by notice in writing
to the Company (or automatically in the event of a Bankruptcy Default), declare all remaining unpaid amounts under this Agreement
(including the unpaid principal amount of the Notes, accrued interest thereon and Make Whole applicable thereto and the unpaid
amount of the Fixed Return, 2(x) Return and Contingent Return) to be immediately due and payable. As liquidated damages and not
as a penalty, the parties are agreed that the amount due on any acceleration on account of the Fixed Return and the 2(x) Return
shall be the maximum distribution payable with respect to such interests under Section 4.1 (after deducting amounts previously
distributed under Section 4.1 with respect to such interests), and the amount due on any acceleration on account of the Contingent
Return, shall be equal to 12% of the “Net Patent FMV”, such being the fair market value of the Patents as of the date
of such acceleration, reduced by the amounts payable on such acceleration on account of the Notes, Fixed Return and 2(x) Return
as of such date; provided, that in the event of a Full Recourse Event, the Net Patent Value shall be deemed increased by the amount
of any reduction in the value of the Patents or Monetization Payments on account of a Bad Act and/or by the amount of any Misappropriation.

 

Notwithstanding anything to the
contrary in this Agreement or any other Document, except as set forth otherwise in Section 8.2.2, the sole and exclusive
recourse of the Investors and the Collateral Agent arising out of or in connection with an uncured Event of Default or any other
breach of this Agreement or any other Document by the Company shall be the recourse set forth in this Sections 8.2.1.1 through
8.2.1.5, and the Investors and Collateral Agent each agree that they will not, individually or collectively, seek to enforce
any monetary judgment with respect to or against any assets of the Company other than the Patents and any Monetization Payments,
and any enforcement of any monetary judgment with respect to or against the Patents or Monetization Payments shall be pursuant
to and in accordance with the terms and conditions of the Collateral Documents.

 

8.2.2.     Additional
Remedies in the Event of Bad Acts. Notwithstanding any other provision hereof, to the extent that an Event of Default arises
either (x) on account of payments required to be made to the Investors or the Collateral Agent or deposited into the Collateral
Account being retained by the Company or utilized by the Company for a different purpose (and following, except where an Event
of Default under Section 8.1.9 is continuing, three (3) Business Days’ notice and an opportunity to cure as specified
above), or (y) on account of any deliberate improper or grossly negligent action (or inaction) by the Company or DSS that materially
and adversely affects the value of the Patents or of the Monetization Payments (in the case of clause (x), a “Misappropriation”
and in the case of clause (y), a “Bad Act” and, either a Misappropriation or a Bad Act, a “Full Recourse
Event”), then the Investors and the Collateral Agent shall have full recourse to, and may pursue any and all assets of,
the Company and DSS to recover any and all amounts owing to them hereunder.

 

If the Majority Investors believe
that a Full Recourse Event has occurred, and they wish to invoke the additional remedies provided for in this Section 8.2.2,
they or the Collateral Agent shall provide notice to the Company that they believe that a Full Recourse Event has occurred, except
that no notice shall be required if an insolvency proceeding is pending with respect to the Company or DSS. Such notice shall set
forth with reasonable specificity the basis for the assertion that a Full Recourse Event has occurred.

 

    	-20-

    	 

    

 

The determination of the Investors
that a Misappropriation has occurred shall be conclusive absent demonstrable error. In the event that the Investors have asserted
that a Bad Act has occurred, then to the extent that the Company disputes this assertion with reasonable specificity in a written
notice within 30 days of such notice, it shall be the Investors’ burden to demonstrate that the value of the Patents or the
Monetization Payments have been materially and adversely affected by an action or omission of the Company or DSS, but it shall
be the Company’s burden to establish that such action or omission was not grossly negligent or deliberately improper.

 

Upon a Full Recourse Event, then
the Investors’ rights shall not be limited to pursuing the Collateral or to the specific remedies set forth in Section
8.2.1, but shall, in addition, have the right to exercise remedies against, and pursue any and all assets of, the Company or
DSS, and DSS agrees and acknowledges that in such event they are full guarantors of the payment (not collectability) of the Company’s
obligations hereunder.

 

8.2.3.     Cumulative
Remedies. To the extent not prohibited by applicable law which cannot be waived, and subject to the last paragraph of Section
8.2.1, each party’s rights hereunder and under the other Documents shall be cumulative; provided that, effective
upon the Majority Investors (or the Collateral Agent, acting at the direction of the Majority Investors) enforcing any remedies
under this Agreement or any other Document, the Investors and the Collateral Agent shall grant, and do hereby grant, to the Company
a perpetual, non-transferable, non-exclusive, royalty-free, worldwide license to the Patents (without the right to sub-license)
in order to permit the Company to use the Patents to sell their products and to comply with arrangements entered into prior to
the date of the applicable Event of Default subject, in the case of such arrangements entered into following the Initial Closing
Date, to such arrangements having been entered into in compliance with this Agreement.

 

8.3.        Annulment
of Defaults. Once an Event of Default has occurred, such Event of Default shall be deemed to exist and be continuing for all
purposes of this Agreement until the Majority Investors shall have waived such Event of Default in writing, the Company shall have
cured such Event of Default to the Majority Investors’ reasonable satisfaction or the Company, the Collateral Agent and the
Investors or Majority Investors have entered into an amendment to this Agreement which by its express terms cures such Event of
Default, at which time such Event of Default shall no longer be deemed to exist or to have continued. No such action by the parties
hereto shall prevent the occurrence of, or effect a waiver with respect to, any subsequent Event of Default or impair any rights
of the parties hereto upon the occurrence thereof.

 

8.4.        Waivers.
To the extent that such waiver is not prohibited by the provisions of applicable law that cannot be waived, Company waives:

 

    	-21-

    	 

    

 

8.4.1.     all
presentments, demands for performance, notices of nonperformance (except to the extent required by this Agreement), protests, notices
of protest and notices of dishonor;

 

8.4.2.     any
requirement of diligence or promptness on the part of the Investors in the enforcement of its rights under this Agreement;

 

8.4.3.     any
and all notices of every kind and description which may be required to be given by any statute or rule of law; and

 

8.4.4.     any
defense (other than indefeasible payment in full) which it may now or hereafter have with respect to its liability under this Agreement
or with respect to the Obligations.

 

ARTICLE IX

COLLATERAL AGENT

 

9.1.        Appointment
of Collateral Agent. Each of the Investors hereby appoints Fortress Credit Co LLC as Collateral Agent to act for them as collateral
agent, to hold any pledged collateral and any other collateral perfected by perfection or control for the benefit of the Investors.

 

9.2.        Collateral.
The Collateral Agent shall act at the instruction of the Majority Investors with respect to providing any vote, consent or taking
other action with respect to the Collateral.

 

9.3.        Collateral
Agent’s Resignation. The Collateral Agent may resign at any time by giving at least 30 days’ prior written
notice of its intention to do so to each of the other parties hereto and upon the appointment by the Majority Investors of a successor
Collateral Agent. If no successor Collateral Agent shall have been so appointed and shall have accepted such appointment within
45 days after the retiring Collateral Agent’s giving of such notice of resignation, then the retiring Collateral Agent may
appoint a successor Collateral Agent, with the consent of the Majority Investors. Upon the appointment of a new Collateral Agent
hereunder, the term “Collateral Agent” shall for all purposes of this Agreement thereafter mean such successor.
After any retiring Collateral Agent’s resignation hereunder as Collateral Agent, or the removal hereunder of any successor
Collateral Agent, the provisions of this Agreement shall continue to inure to the benefit of such retiring or removed Collateral
Agent as to any actions taken or omitted to be taken by it while it was Collateral Agent under this Agreement.

 

9.4.        Concerning
the Collateral Agent.

 

9.4.1.     Standard
of Conduct, etc. The Collateral Agent and its officers, directors, employees and agents shall be under no liability to any
of the Investors or to any future holder of any interest in the Obligations for any action or failure to act taken or suffered
in the absence of gross negligence and willful misconduct, and any action or failure to act in accordance with an opinion of its
counsel shall conclusively be deemed to be in the absence of gross negligence and willful misconduct.

 

    	-22-

    	 

    

 

9.4.2.     No
Implied Duties, etc. The Collateral Agent shall have and may exercise such powers as are specifically delegated to the Collateral
Agent under this Agreement together with all other powers incidental thereto. The Collateral Agent shall have no implied duties
to any Person or any obligation to take any action under this Agreement except for action specifically provided for in this Agreement
to be taken by the Collateral Agent.

 

9.4.3.     Validity,
etc. The Collateral Agent shall not be responsible to any other party or any future holder of any interest in the Obligations
(a) for the legality, validity, enforceability or effectiveness of any Document, (b) for any recitals, reports, representations,
warranties or statements contained in or made in connection with any Document, (c) for the existence or value of any assets included
in any security for the Obligations, (d) for the effectiveness of any Lien purported to be included in the security for the Obligations,
or (e) for the perfection of the security interests for the Obligations.

 

9.4.4.     Compliance.
The Collateral Agent shall not be obligated to ascertain or inquire as to the performance or observance of any of the terms of
this Agreement or any other Document.

 

9.4.5.     Employment
of Agents and Counsel. The Collateral Agent may execute any of its duties as Collateral Agent under this Agreement or the other
Documents by or through employees, agents and attorneys-in-fact and shall not be responsible to any of the parties hereto for the
default or misconduct of any such employees, agents or attorneys-in-fact selected by the Collateral Agent acting in the absence
of gross negligence and willful misconduct. The Collateral Agent shall be entitled to advice of counsel concerning all matters
pertaining to the agency hereby created and its duties hereunder.

 

9.4.6.     Reliance
on Documents and Counsel. The Collateral Agent shall be entitled to rely, and shall be fully protected in relying, upon any
affidavit, certificate, cablegram, consent, instrument, letter, notice, order, document, statement, telecopy, telegram, telex or
teletype message or writing reasonably believed in good faith by the Collateral Agent to be genuine and correct and to have been
signed, sent or made by the Person in question, including any telephonic or oral statement made by such Person, and, with respect
to legal matters, upon an opinion or the advice of counsel selected by the Collateral Agent.

 

9.4.7.     Collateral
Agent’s Reimbursement. The Investors agree to indemnify the Collateral Agent for any losses arising from its appointment
as the Collateral Agent or from the performance of its duties hereunder and to reimburse the Collateral Agent for any reasonable
expenses; provided, however, that the Collateral Agent shall not be indemnified or reimbursed for liabilities or
expenses to the extent resulting from its own gross negligence or willful misconduct.

 

    	-23-

    	 

    

 

9.4.8.     Assumption
of Collateral Agent’s Rights. Notwithstanding anything herein to the contrary, if at any time no Person
constitutes the Collateral Agent hereunder or the Collateral Agent fails to act upon written directions from the parties hereto,
the Majority Investors shall be entitled to exercise any power, right or privilege granted to the Collateral Agent and in so acting
the Majority Investors shall have the same rights, privileges, indemnities and protections provided to the Collateral Agent hereunder.

 

ARTICLE X

GENERAL PROVISIONS

 

10.1.      Expenses.
The Company agrees to promptly pay in full (i) all reasonable out-of-pocket costs and expenses (including, without limitation,
reasonable fees and disbursements of a external counsel) incurred, by the Collateral Agent or the Investors in connection with
(w) the negotiation and documentation of the Documents in an amount not to exceed seventy five thousand dollars ($75,000), (x)
the expenses that the Company is responsible for pursuant to Section 7.5.2, and (y) any reasonable action taken by the Collateral
Agent or any Investor pursuant to Section 7.8.3 and Section 10.11, (ii) all reasonable out-of-pocket costs and expenses
(including, without limitation, reasonable fees and disbursements of a single external counsel and any local counsel in any relevant
jurisdiction) incurred by the Collateral Agent or the Investors in connection up with establishing and administrating the special
purpose entity referred to in Section 7.6 or Section 8.2.1.3, (iii) all reasonable out-of-pocket costs and expenses
(including, without limitation, reasonable fees and disbursements of a single external counsel and any local counsel in any relevant
jurisdiction) incurred by the Collateral Agent or the Investors in enforcing any obligations hereunder or in collecting any payments
due hereunder by reason of such Event of Default, including broker’s fees and other third party professional fees and expenses
and (iv) all reasonable out-of-pocket costs and expenses (including, without limitation, reasonable fees and disbursements of a
external counsel) incurred by the Collateral Agent or the Investors in connection with any refinancing or restructuring of the
credit arrangements provided under the Documents in the nature of a workout, or any insolvency or bankruptcy proceedings. Any such
costs and expenses invoiced prior to the Initial Closing Date shall be paid on the Initial Closing Date. Any other costs and expenses
shall be paid within thirty (30) days of the submission of an invoice to the Company therefor. Any amounts not timely paid shall
bear interest, payable in cash, at a rate of 10% per annum compounding quarterly. This Section 10.1 shall survive termination
of this Agreement.

 

    	-24-

    	 

    

 

10.2.      Indemnity.
In addition to the payment of expenses pursuant to Section 10.1, whether or not the transactions contemplated hereby
shall be consummated, the Company (as “Indemnitor”) agrees to indemnify, pay and hold the Collateral Agent and
the Investors, and the officers, directors, partners, managers, members, employees, agents, and Affiliates of the Collateral Agent
or the Investors (collectively, the “Indemnitees”) harmless from and against any and all other liabilities,
costs, expenses, obligations, losses (other than lost profit), damages, penalties, actions, judgments, suits, claims and disbursements
of any kind or nature whatsoever (including, without limitation, the reasonable fees and disbursements of one counsel for such
Indemnitees) in connection with any investigative, administrative or judicial proceeding commenced or threatened by a third party
(excluding claims among Indemnitees), whether or not such Indemnitee shall be designated a party thereto, which may be imposed
on, incurred by, or asserted against that Indemnitee by a third party, in any manner relating to or arising out of any Document
(the “Indemnified Liabilities”); provided, that the Indemnitor shall not have any obligation to an Indemnitee
hereunder with respect to an Indemnified Liability to the extent that such Indemnified Liability arises from the gross negligence
or willful misconduct of that Indemnitee or any of its officers, directors, partners, managers, members, employees, agents and/or
Affiliates. Each Indemnitee shall give the Indemnitor prompt written notice of any claim that might give rise to Indemnified Liabilities
setting forth a description of those elements of such claim of which such Indemnitee has knowledge; provided, that any failure
to give such notice shall not affect the obligations of the Indemnitor. The Indemnitor shall have the right at any time during
which such claim is pending to select counsel to defend and control the defense thereof and settle any claims for which it is responsible
for indemnification hereunder (provided that the Indemnitor will not settle any such claim without (i) the appropriate Indemnitee’s
prior written consent, which consent shall not be unreasonably withheld or (ii) obtaining an unconditional release of the appropriate
Indemnitee from all claims arising out of or in any way relating to the circumstances involving such claim and without any admission
as to culpability or fault of such Indemnitee) so long as in any such event, the Indemnitor shall have stated in a writing delivered
to the Indemnitee that, as between the Indemnitor and the Indemnitee, the Indemnitor is responsible to the Indemnitee with respect
to such claim to the extent and subject to the limitations set forth herein; provided, that the Indemnitor shall not be
entitled to control the defense of any claim in the event that in the reasonable opinion of counsel for the Indemnitee, there are
one or more material defenses available to the Indemnitee which are not available to the Indemnitor; provided further,
that with respect to any claim as to which the Indemnitee is controlling the defense, the Indemnitor will not be liable to any
Indemnitee for any settlement of any claim pursuant to this Section 10.2 that is effected without its prior written
consent, which consent shall not be unreasonably withheld. To the extent that the undertaking to indemnify, pay and hold harmless
set forth in this Section 10.2 may be unenforceable because it is violative of any law or public policy, the Company
shall contribute the maximum portion which it is permitted to pay and satisfy under applicable law, to the payment and satisfaction
of all Indemnified Liabilities incurred by the Indemnitees or any of them. This Section 10.2 shall survive termination of
this Agreement.

 

10.3.      Notices.
All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement or
any other Document shall be in writing and delivered via facsimile, email (in each case, followed promptly by delivery from a nationally
recognized overnight courier) or a nationally recognized overnight courier. Such notices, demands and other communications will
be delivered or sent to the address indicated on Schedule 10.3 or such other address or to the attention of such other Person
as the recipient party shall have specified by prior written notice to the sending party. Any such communication shall be deemed
to have been received when actually delivered or refused.

 

10.4.      Amendments,
Consents, Waivers, etc.

 

10.4.1.   Amendments.
No amendment, modification, termination or waiver of any provision of this Agreement or any other Document shall in any event be
effective without the written consent of the Company, the Collateral Agent and the Majority Investors; provided that the
consent of each affected Investor shall be required for any amendment that (i) waives or reduces any amounts owed to it under this
Agreement or extends the date for payment of any amount hereunder, or (ii) releases all or any material portion of the Collateral.
Any waiver or consent shall be effective only in the specific instance and for the specific purpose for which it was given. No
notice to or demand on the Company in any case shall entitle the Company to any further notice or demand in similar or other circumstances.
Any amendment, modification, termination, waiver or consent effected in accordance with this Section 10.4.1 shall be binding
upon the holders of the Obligations at the time outstanding and each future holder thereof.

 

    	-25-

    	 

    

 

10.4.2.   Course
of Dealing; No Implied Waivers. No course of dealing between the Investors and the Company shall operate as a waiver of any
Investor’s rights under this Agreement, any other Document or with respect to the Obligations. In particular, no delay or
omission on the part of any Investor in exercising any right under this Agreement, any other Document or with respect to the Obligations
shall operate as a waiver of such right or any other right hereunder or thereunder. A waiver on any one occasion shall not be construed
as a bar to or waiver of any right or remedy on any future occasion.

 

10.5.      No
Strict Construction. The parties have participated jointly in the negotiation and drafting of the Documents with counsel sophisticated
in financing transactions. In the event an ambiguity or question of intent or interpretation arises, the Documents shall be construed
as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue
of the authorship of any provisions of the Documents.

 

10.6.      Certain
Acknowledgments. Each of the Company and the Investors acknowledges that:

 

10.6.1.   it
has been advised by counsel in the negotiation, execution and delivery of the Documents; and

 

10.6.2.   no
joint venture is created hereby or otherwise exists by virtue of the transactions contemplated hereby or thereby among the Company
and the Investors.

 

10.7.      Venue;
Service of Process; Certain Waivers. The Company and Investor:

 

10.7.1.   irrevocably
submit to the exclusive jurisdiction of any New York state court or federal court sitting in New York, New York, and any court
having jurisdiction over appeals of matters heard in such courts, for the purpose of any suit, action or other proceeding arising
out of or based upon any Document or the subject matter hereof or thereof;

 

10.7.2.   waives
to the extent not prohibited by applicable law that cannot be waived, and agrees not to assert, by way of motion, as a defense
or otherwise, in any such proceeding brought in any of the above-named courts, any claim that it is not subject personally to the
jurisdiction of such court, that its property is exempt or immune from attachment or execution, that such proceeding is brought
in an inconvenient forum, that the venue of such proceeding is improper, or that any Document, or the subject matter hereof or
thereof, may not be enforced in or by such court;

 

    	-26-

    	 

    

 

10.7.3.   consents
to service of process in any such proceeding in any manner at the time permitted under the applicable laws of the State of New
York and agrees that service of process by registered or certified mail, return receipt requested, at its address specified pursuant
to Section 10.3 is reasonably calculated to give actual notice; and

 

10.7.4.   waives
to the extent not prohibited by applicable law that cannot be waived any right it may have to claim or recover in any such proceeding
any special, exemplary, punitive or consequential damages.

 

10.8.      WAIVER
OF JURY TRIAL. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, THE COMPANY AND EACH INVESTOR WAIVES,
AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY FORUM IN
RESPECT OF ANY ISSUE, CLAIM OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, ANY OTHER DOCUMENT OR THE CONDUCT OF THE
PARTIES HERETO, WHETHER NOW EXISTING OR HEREAFTER ARISING AND WHETHER IN CONTRACT, TORT OR OTHERWISE. The Company acknowledges
that it has been informed by the Investors that the foregoing sentence constitutes a material inducement upon which the Investors
have relied and will rely in entering into this Agreement and the other Documents. Any of the Company or Investors may file an
original counterpart or a copy of this Agreement and any other Document with any court as written evidence of the consent of the
Company and Investors to the waiver of their rights to trial by jury.

 

10.9.      Interpretation;
Governing Law; etc. All covenants, agreements, representations and warranties made in this Agreement, any other Document or
in certificates delivered pursuant hereto or thereto shall be deemed to have been relied on by each Investor, notwithstanding any
investigation made by such Investor, and shall survive the execution and delivery to the Investors hereof and thereof. The invalidity
or unenforceability of any provision hereof shall not affect the validity or enforceability of any other provision hereof, and
any invalid or unenforceable provision shall be modified so as to be enforced to the maximum extent of its validity or enforceability.
The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.
This Agreement and the Documents constitute the entire understanding of the parties with respect to the subject matter hereof and
thereof and supersede all prior and contemporaneous understandings and agreements, whether written or oral. This Agreement may
be executed in any number of counterparts which together shall constitute one instrument. This Agreement and the other Documents
may be executed by electronic (including .pdf) means. This Agreement, and any issue, claim or proceeding arising out of or relating
to this Agreement or the Documents or the conduct of the parties hereto, whether now existing or hereafter arising and whether
in contract, tort or otherwise, shall be governed by and construed in accordance with the laws of the State of New York.

 

10.10.    Successors
and Assigns

 

10.10.1. The
provisions of this Agreement and the other Documents shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns permitted by Sections 10.10.2 and 10.10.3.

 

    	-27-

    	 

    

 

10.10.2. Except
in connection with an assignment of the Patents to a special purpose entity required under this Agreement, the Company may not
assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Majority Investors.

 

10.10.3. Subject
to Section 10.10.4 below, any Investor may sell, assign, participate or transfer all or any part of their rights under this
Agreement and the other Documents; provided that such Investors and the assignee of such Investor shall have delivered an
executed Assignment and Assumption Agreement substantially in the form attached hereto as Exhibit A to the Company and each
other Investor. In the case of any sale, assignment, transfer or negotiation of all or part of the rights of an Investor under
this Agreement that is authorized under this Section 10.10.3, the assignee, transferee or recipient shall have, to
the extent of such sale, assignment, transfer or negotiation, the same rights, benefits and obligations as it would if it were
an Investor hereunder. The Investors agree to provide to the Company prompt written notice of any sales, assignments or transfers
permitted hereunder, including the name and address of the transferee(s). For the avoidance of doubt, subject to the restriction
set forth in this Section 10.10, the Notes, Fixed Return Interest and Contingent Interest shall be separately transferable.

 

10.10.4. The
Company shall maintain at its principal office, or the principal office of its counsel, a register (the “Register”)
in which the Company shall keep a record of the Advances made by each Investor, payments to each Investor and any transfer of the
rights of an Investor; provided that the Company shall have no obligation to update the register to reflect any sales, assignments
or transfers made by the Investors in the event that the Investors fail to give the Company written notice as required under Section
10.10.3. The requirement that the ownership and transfer of the rights of the Investors under this Agreement shall be reflected
in the Register is intended to ensure that the Advances qualify as an obligation issued in “registered form” as that
term is used in Sections 163(f), 871(h), and 881(c) of the Code and shall be interpreted accordingly and, notwithstanding anything
to the contrary in this Agreement.

 

10.11.    Tax
Treatment.

 

10.11.1. Each
Fixed Return Interest Purchaser and Contingent Interest Purchaser and the Company intend that, solely for federal, state and local
income tax purposes and for no other purpose, the relationship between the Fixed Return Interest Purchasers and Contingent Interest
Purchasers and the Company that is created by this Agreement shall be treated as creating a partnership (the “Tax Partnership”),
with the Fixed Return Interest Purchasers and Contingent Interest Purchasers and the Company being treated as partners of such
partnership, and the Fixed Return Interest Purchasers and Contingent Interest Purchasers and the Company shall be treated as having
received amounts to which they are entitled under Section 4.1 and Section 4.2 in their capacities as partners of
such partnership. For the avoidance of doubt, Note Purchasers, solely in their capacity as such, shall not be treated as partners
in the Tax Partnership and amounts received by the Note Purchasers under this Agreement in respect of the Notes shall not be treated
as being received by, or with respect to, the Tax Partnership.

 

    	-28-

    	 

    

 

10.11.2.   The
Company and each Fixed Return Interest Purchaser and Contingent Interest Purchaser hereby agree that for purposes of determining
the Company’s and each Fixed Return Interest Purchaser’s and Contingent Interest Purchaser’s distributive share
of income, gain, loss and deduction of the Tax Partnership:

 

10.11.2.1.      The
Tax Partnership shall maintain capital accounts for each of the Company and the Fixed Return Interest Purchasers and Contingent
Interest Purchasers consistent with the rules of Treasury Regulations Section 1.704-1(b); it being understood that under no circumstances
shall any such rule override the economic relationship between the parties set forth in Section 4.1 and Section 4.2.

 

10.11.2.2.      The
Company shall be deemed to contribute to the Tax Partnership the right to generate revenue through the exploitation of the Patents
(the “Patent Rights”) with an agreed upon fair market value equal to the amount deemed contributed to the Tax
Partnership by the Fixed Return Interest Purchasers and the Contingent Interest Purchasers in connection with the Initial Advance;
provided, for the purpose of clarity, that the Patent Rights shall not be deemed to include the right to generate revenue
that is payable to the Note Purchasers under this Agreement in respect of the Notes;

 

10.11.2.3.      The
Fixed Return Interest Purchasers shall be deemed to contribute to the Tax Partnership the amounts paid for the Fixed Return Interests
set forth on Schedule 2.1, Schedule 2.2 and Schedule 2.3, and the Contingent Interest Purchasers shall be
deemed to contribute to the Tax Partnership the amount paid for the Contingent Interest set forth on Schedule 2.1;

 

10.11.2.4.      The
Tax Partnership shall allocate items of income, gain, loss and deduction to the Company and the Fixed Return Interest Purchasers
and Contingent Interest Purchasers in a manner that causes the capital accounts of the parties to be equal to the amounts payable
pursuant to this agreement if the Tax Partnership sold the Patent Rights and any other non-cash assets for an amount equal to the
book value of the Patent Rights and any other non-cash assets (as determined pursuant to Treasury Regulations Section 1.704-1(b))
and distributed the proceeds and any cash pursuant to Section 4.1 and Section 4.2. In the event that the capital
accounts of all of the partners in the Tax Partnership have been reduced to zero, any further losses shall be allocated to such
partners in proportion to the amount of cash that would have been distributed to such partners under Section 4.1 and Section
4.2 if the Tax Partnership had distributable cash equal to the amount of such further losses; it being understood that any
subsequent gains shall be allocated to the partners that were allocated such further losses until the effect of the allocation
of such further losses is eliminated.

 

    	-29-

    	 

    

 

10.11.3. Each
Investor and the Company intend that the Notes shall be treated as debt of the Company for all purposes, including for all federal,
state and local income tax purposes, and shall not be treated as debt of the Tax Partnership.

 

10.11.4. Each
Fixed Return Interest Purchaser and Contingent Interest Purchaser and the Company shall file all Tax Returns (as defined below)
and shall otherwise take all tax and financial reporting positions in a manner consistent with this Section 10.11. The Company
shall be the tax matters partner of the Tax Partnership.

 

10.11.5. The
Company and each Fixed Return Interest Purchaser and Contingent Interest Purchaser will cooperate to provide each other with any
information reasonably requested by any of them in connection with the preparation or filing of any return, declaration, report,
election, information return or other statement or form filed or required to be filed with any governmental authority relating
to Taxes (a “Tax Return”) for any of them or for or relating to the Tax Partnership. The Company shall be responsible
for preparing and filing any Tax Return for or relating to the Tax Partnership, provided that the Company shall not file
any Tax Return without the prior consent of the Majority Fixed Return Interest Purchasers and the Majority Contingent Interest
Purchasers. The out-of-pocket costs incurred in connection with the preparation and filing of any Tax Return for or relating to
the Tax Partnership shall be treated as an expense of the Tax Partnership.

 

10.11.6. For
the avoidance of doubt, no fiduciary relationship is intended to be created by this Agreement between the Company and any Fixed
Return Interest Purchaser or Contingent Interest Purchaser.

 

10.12.    Confidentiality.
The Company shall provide the Collateral Agent and the Investors a reasonable opportunity to review and comment on any proposed
press release or other public filing or public disclosure regarding the arrangements reflected in this Agreement and the other
Documents. The Company shall not name the Collateral Agent or the Investors (including by referring to any variation of the name
“Fortress”) in any press release or other public filing or public disclosure without the prior written consent of the
Collateral Agent or such Investor, except where any such disclosure is required by laws or regulations applicable to the Company
and the Company has provided prior written notice to the Collateral Agent and the Investors.

 

(The remainder of this page intentionally
has been left blank.)

 

    	-30-

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have
duly executed this Investment Agreement as of the date and year first above written.

 

	 	Investors:	 
	 	 	 	 
	 	FORTRESS CREDIT CO LLC, as Note Purchaser	 
	 	 	 	 
	 	 	/s/ Constantine M. Dakolias	 
	 	By:	Constantine M. Dakolias	 
	 	Title:	President	 
	 	 	 	 
	 	 	 	 
	 	CF DB EZ LLC, as Fixed Return Interest Purchaser and Contingent Interest Purchaser	 
	 	 	 	 
	 	 	/s/ Constantine M. Dakolias	 
	 	By:	Constantine M. Dakolias	 
	 	Title:	President	 

 

Investment Agreement

 

    	 

    	 

    

 

	 	Collateral Agent:	 
	 	 	 	 
	 	FORTRESS CREDIT CO LLC	 
	 	 	 	 
	 	 	/s/ Constantine M. Dakolias	 
	 	By:	Constantine M. Dakolias	 
	 	Title:	 President	 

 

Investment Agreement

 

    	 

    	 

    

 

	 	Company:	 
	 	 	 	 
	 	DSS TECHNOLOGY MANAGEMENT, INC.	 
	 	 	 	 
	 	 	/s/ Jeffrey Ronaldi	 
	 	By:	Jeffrey Ronaldi	 
	 	Title:	Title: Chief Executive Officer	 
	 	 	 	 
	 	 	 	 
	 	Affiliates:	 
	 	 	 	 
	 	Document Security Systems, Inc. (for purposes of Section 8.2.2 only)	 
	 	 	 	 
	 	 	/s/ Jeffrey Ronaldi	 
	 	By:	 Jeffrey Ronaldi	 
	 	Title:	Chief Executive Officer	 

 

Investment Agreement

 

    	 

    	 

    

 

APPENDIX
I

 

DEFINITIONS

 

“2(x) Return” means payment
to the Contingent Interest Purchasers of two times the purchase price for the Contingent Interest reflected on Schedule 2.1.

 

“Affiliate” means with
respect to any specified Person, any other Person directly or indirectly controlling, controlled by or under direct or indirect
common control with such Person, and shall include (a) any officer or director or general partner of such specified Person, (b)
any other Person of which such specified Person or any Affiliate (as defined in clause (a) above) of such specified Person shall,
directly or indirectly, beneficially own either (i) at least 50% of the outstanding equity securities having the general power
to vote or (ii) at least 50% of all equity interests, (c) any other Person directly or indirectly controlling such specified Person
through a management agreement, voting agreement or other contract and (d) with respect to any individual, such individual’s
child, stepchild, grandchild or more remote descendant, parent, stepparent, grandparent, spouse, former spouse, qualified domestic
partner, sibling, mother-in-law, father-in-law, son-in-law and daughter-in-law (including adoptive relationships) and any trust,
partnership or other bona fide estate-planning vehicle the only beneficiaries of which are any of the foregoing individuals or
any private foundation or fund that is controlled by any of the foregoing individuals or any donor-advised fund of which any such
individual is the donor; provided that neither the Collateral Agent or any Investor shall be deemed an Affiliate of the Company
on account of the amounts owed to it under this Investment Agreement or the relationship created thereby.

 

“Applicable Federal Rate”
means the applicable federal rate as determined by the Internal Revenue Service pursuant to Section 1274(d) of the Code and as
in effect on the Closing Date; provided that the Applicable Federal Rate for any Note shall be determined as of the applicable
Closing Date for such Note based upon the term of the Note from such date to its maturity date, it being understood and agreed
that the Applicable Federal Rate for the Notes issued on the Closing Date is 1.95%.

 

“Applicable Percentage”
means (i) if a U.S. District Court has conducted a claim construction hearing following the Initial Closing Date to construe one
or more disputed patent claim terms in an infringement action, wherein one or more of the Patents listed on Schedule I(a)
has been asserted, 60% and (ii) otherwise, 65%.

 

“Authorized Officer”
means, with respect to any Person, the chief executive officer, chief restructuring officer, chief financial officer, president,
treasurer, comptroller or executive vice president of such Person.

 

“Bankruptcy Code” means
Title 11 of the United States Code.

 

“Bankruptcy Default”
means an Event of Default referred to in Section 8.1.9.

 

    	A-1

    	 

    

 

“Business Day” means
any day other than a Saturday, a Sunday or a day on which commercial banks in New York City are required or authorized to be closed.

 

“Capitalized Lease” means
any lease which is required to be capitalized on the balance sheet of the lessee in accordance with GAAP, including Statement Nos.
13 and 98 of the Financial Accounting Standards Board.

 

“Capitalized Lease Obligations”
means the amount of the liability reflecting the aggregate discounted amount of future payments under all Capitalized Leases in
accordance with GAAP, including Statement Nos. 13 and 98 of the Financial Accounting Standards Board.

 

“Change of Control” means
(x) Document Security Systems, Inc., a New York corporation a shall cease to own, directly or indirectly, 100% of the outstanding
equity interest of the Company or (y) any Person or “group” (as such term is used in Sections 13(d) and 14(d)
of the Securities Exchange Act of 1934, but excluding any employee benefit plan of such Person and its Subsidiaries, and any Person
acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan), becomes the “beneficial owner”
(as defined in Rules 13(d)-3 and 13(d)-5 of the Securities Exchange Act of 1934), directly or indirectly, of equity interests
representing more than thirty percent (30%) of the aggregate ordinary voting power represented by the issued and outstanding equity
interests of Document Security Systems, Inc. a New York corporation.

 

“Closing Date” means
each of (i) the Initial Closing Date, (ii) the First Milestone Closing Date and (iii) the Second Milestone Closing Date.

 

“Code”
means the Internal Revenue Code of 1986, as amended.         

 

“Collateral” has the
meaning set forth in the Security Agreement.

 

“Collateral Documents”
means the Security Agreement, the Patent Security Agreement, any financing statement (or amendment thereto) naming the Company
as debtor and the Collateral Agent as secured party, and all other instruments, documents, agreements and certificates delivered
by the Company to the Investors or the Collateral Agent pursuant to these agreements.

 

“Contingent Interest”
means, after the Note Purchasers and Fixed Return Interest Purchasers have received payment in full, the 2(x) Return plus 12% of
all Gross Receipts thereafter.

 

“Contractual Obligations”
means, as to any Person, any provision of any security (whether in the nature of capital stock or otherwise) issued by such Person
or of any agreement, undertaking, contract, indenture, mortgage, deed of trust or other instrument, document or agreement (other
than a Document) to which such Person is a party or by which it or any of its property is bound or to which any of its property
is subject.

 

    	A-2

    	 

    

 

“Debtor Relief Laws”
means the Bankruptcy Code of the United States and all other liquidation, conservatorship, bankruptcy, assignment for the benefit
of creditors, moratorium, rearrangement, receivership, insolvency, reorganization or similar debtor relief laws of the United States
or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally.

 

“Default” means any Event
of Default and any event or condition which with the passage of time or giving of notice, or both, would become an Event of Default.

 

“Disposition” means any
sale, transfer, license, profit or revenue sharing arrangements (including contingency fee arrangements), derivative interests,
lease or other disposition (including any sale or issuance of equity interests in the Company) of any property by any Person, including
any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and
claims associated therewith, whether in a single transaction or a series of related transactions. “Dispose” shall have
the correlative meaning.

 

“Documents” means this
Agreement, the Collateral Documents, the agreements referenced in Section 5.1.1.5 and all other instruments, documents,
agreements and certificates delivered by the Company to the Investors pursuant to this Agreement.

 

“First Milestone” means
the filing of a compliant after the Initial Closing Date wherein the Company asserts and alleges infringement by a third-party
of one or more of the Patents.

 

“First Milestone Closing Date”
means the date upon which the conditions set forth in Section 5.2 have been satisfied.

 

“Fixed Return” means
payment to the Fixed Return Interest Purchasers of 10.1 times the purchase price for the applicable Fixed Return Interests as reflected
on Schedules 2.1, 2.2 and 2.3.

 

“Fixed Return Interest”
means, after the Notes have been paid in full, payment of the Fixed Return.

 

“GAAP” means generally
accepted accounting principles as from time to time in effect, including the statements and interpretations of the United States
Financial Accounting Standards Board.

 

“Gross Receipts” means
any and all Monetization Payments as and when actually received by the Company (including any and all Monetization Payments actually
received by any attorneys, agents or other representatives of the Company) following the Initial Closing Date. Gross Receipts shall
be calculated prior to giving effect to (x) any expenses incurred by the Company in the collection of any Monetization Payments,
including, without limitation, prior to giving effect to any contingent or other fees owed to any attorneys, consultants or other
professionals in connection with any Monetization Activities and (y) any interest in the Patents retained by any other Person.

 

    	A-3

    	 

    

 

“Guarantee” means, with
respect to any specified Person:

 

(a)          any
guarantee by such Person of the payment or performance of, or any contingent obligation by such Person in respect of, any Indebtedness
or other obligation of any primary obligor;

 

(b)          any
other arrangement whereby credit is extended to a primary obligor on the basis of any promise or undertaking of such Person, including
any binding “comfort letter” or “keep well agreement” written by such Person, to a creditor or prospective
creditor of such primary obligor, to (i) pay the Indebtedness of such primary obligor, (ii) purchase an obligation owed by such
primary obligor, (iii) pay for the purchase or lease of assets or services regardless of the actual delivery thereof or (iv) maintain
the capital, working capital, solvency or general financial condition of such primary obligor;

 

(c)          any
liability of such Person, as a general partner of a partnership in respect of Indebtedness or other obligations of such partnership;

 

(d)          any
liability of such Person as a joint venturer of a joint venture in respect of Indebtedness or other obligations of such joint venture;

 

(e)          any
liability of such Person with respect to the tax liability of others as a member of a group (other than a group consisting solely
of such Person and its Subsidiaries) that is consolidated for tax purposes; and

 

(f)           reimbursement
obligations, whether contingent or matured, of such Person with respect to letters of credit, bankers acceptances, surety bonds
and other financial guarantees;

 

in each case whether or not any
of the foregoing are reflected on the balance sheet of such Person or in a footnote thereto.

 

“Indebtedness” means
all obligations, contingent or otherwise, which in accordance with GAAP are required to be classified upon the consolidated balance
sheet of the Company as liabilities, but in any event including (without duplication):

 

(a)          indebtedness
for borrowed money;

 

(b)          indebtedness
evidenced by notes, debentures or similar instruments;

 

(c)          Capitalized
Lease Obligations and Synthetic Lease Obligations;

 

(d)          the
deferred purchase price of assets, services or securities, including related noncompetition, consulting and stock repurchase obligations
(other than ordinary trade accounts payable on customary terms in the ordinary course of business), and any long-term contractual
obligations for the payment of money, but not including contingent fees payable to counsel;

 

    	A-4

    	 

    

 

(e)          mandatory
redemption, repurchase or dividend rights on capital stock (or other equity), including provisions that require the exchange of
such capital stock (or other equity) for Indebtedness from the issuer;

 

(f)           reimbursement
obligations, whether contingent or matured, with respect to letters of credit, bankers acceptances, surety bonds and other financial
guarantees (without duplication of other Indebtedness supported or guaranteed thereby);

 

(g)          unfunded
pension liabilities;

 

(h)          obligations
that are immediately and directly due and payable out of the proceeds of or production from property, but not including contingent
fees payable to counsel;

 

(i)           liabilities
secured by any Lien existing on property owned or acquired by the Company, whether or not the liability secured thereby shall have
been assumed; and

 

(j)           all
Guarantees in respect of Indebtedness of others and reimbursement obligations, whether contingent or matured, under letters of
credit or other financial guarantees by third parties (or become contractually committed to do so).

 

“Initial Closing Date”
means February 12, 2014.

 

“Investors” means the
Note Purchasers, the Fixed Return Interest Purchasers and the Contingent Interest Purchasers.

 

“Legal Requirement” means,
with respect to any specified Person, any present or future requirement imposed upon such Person and its Subsidiaries by any law,
statute, rule, regulation, directive, order, decree or guideline (or any interpretation thereof by courts or of administrative
bodies) of the United States of America or any state or political subdivision thereof, governmental or administrative agency, central
bank or monetary authority of the United States of America, any jurisdiction where the such Person or any of its Subsidiaries owns
property or conducts its business, or any political subdivision of any of the foregoing.

 

“Lien” means
with respect to any specified Person:

 

(a)          any
lien, encumbrance, mortgage, pledge, charge or security interest of any kind upon any property or assets of such Person, whether
now owned or hereafter acquired, or upon the income or profits therefrom (excluding in any event a financing statement filed by
a lessor under an operating lease not intended to be a secured financing), but shall not include: (i) liens for any tax, assessment
or other governmental charge not yet due or that are being contested in good faith by appropriate proceeding, (ii) materialmen’s
and mechanics’ liens or other like Liens, arising in the ordinary course of business for amounts not yet due or that are
being contested in good faith; and (iii) liens, deposits or pledges to secure statutory obligations or performance of bids, tenders,
contracts or leases, incurred in the ordinary course of business;

 

    	A-5

    	 

    

 

(b)          the
acquisition of, or the agreement to acquire, any property or asset upon conditional sale or subject to any other title retention
agreement, device or arrangement (including a Capitalized Lease and a Synthetic Lease);

 

(c)          the
sale, assignment, pledge or transfer for security of any accounts, general intangibles or chattel paper of such Person, with or
without recourse;

 

(d)          in
the case of securities, any purchase option, call or similar purchase right of a third party;

 

(e)          the
existence for a period of more than 120 consecutive days of any Indebtedness against such Person which if unpaid would by law or
upon a Bankruptcy Default be given priority over general creditors.

 

“Majority Contingent Interest Purchasers”
means the Contingent Interest Purchasers that hold more than 50% of the Contingent Interest.

 

“Majority Investors”
means (i) until such time as the Notes have been paid in full, the Majority Note Purchasers (ii) after the Notes have been paid
in full, the Majority Fixed Return Interest Purchasers and (iii) after the Fixed Return Interest Purchasers have been paid in full,
the Majority Contingent Interest Purchasers.

 

“Majority Note Purchasers”
means the Note Purchasers that hold more than 50% of the aggregate outstanding Notes.

 

“Majority Fixed Return Interest
Purchasers” means Fixed Return Interest Purchasers representing more than 50% of such participation right.

 

“Make Whole Amount” means,
with respect to any Note, an amount equal to (a) the product of (i) the original principal amount of such Note (exclusive of any
Capitalized Interest) and (ii) 1.10 minus (b) the amount of principal and interest actually paid in cash in respect of such
Note.

 

“Margin Stock” means
“margin stock” within the meaning of Regulation T, U or X of the Board of Governors of the Federal Reserve System.

 

“Material Adverse Effect”
means, with respect to any Person, since any specified date or from the circumstances existing immediately prior to the happening
of any specified event, a material adverse effect on the business, assets, financial condition, income or prospects of such Person
or any of its Subsidiaries.

 

“Maturity Date” means the date
which is four years after the Initial Closing Date.

 

“Monetization Activities”
means any activities necessary or desirable to generate revenue from intellectual property anywhere in the world by means of license
(non-exclusive or exclusive), assignment, enforcement, litigation, arbitration, negotiation, covenant not to sue or assert, or
otherwise.

 

    	A-6

    	 

    

 

“Monetization Payments”
means any amounts that the Company receives in cash from third parties, including royalty payments, license fees, settlement payments,
judgments or other similar payments in respect of the Patents owned by or exclusively licensed to a Company, in each case as and
when actually received by the Company (including any and all such amounts actually received by any attorneys, agents or other representatives
of the Company)

 

“Notes” means the notes
issued pursuant to Section 2.1., 2.2 and 2.3, each substantially in the form of Exhibit E through Exhibit
G.

 

“Obligations” means any
and all obligations of the Company under this Agreement or any other Document, including all amounts pursuant to Articles III
and IV and Sections 10.1 and 10.2.

 

“Organization Documents”
means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or equivalent or comparable
constitutive documents with respect to any non-U.S. jurisdiction); (b) with respect to any limited liability company, the certificate
or articles of formation or organization and operating agreement; and (c) with respect to any partnership, joint venture, trust
or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization and
any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the
applicable governmental authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles
of formation or organization of such entity.

 

“Patent Security Agreement”
means a Patent Security Agreement substantially in the form of Exhibit B hereto.

 

“Patent License” means
the Patent License attached hereto as Exhibit C.

 

“Patents” means the letters
patent of the United States set forth on Schedule I(b), including all registrations and recordings thereof, all applications
for letters patent of the United States or any other jurisdiction, all re-examination certificates and all utility models, including
registrations, recordings and pending applications, and all reissues, continuations, divisions, continuations-in-part, renewals
or extensions thereof, and the inventions claimed therein.

 

“Permitted Indebtedness”
means Indebtedness in respect of the Obligations and Indebtedness existing on the date hereof and set forth on Schedule I(c).

 

“Person” means any entity,
whether of natural or legal constitution, including any present or future individual, corporation, partnership, joint venture,
limited liability company, unlimited liability company, trust, estate, unincorporated organization, government or any agency or
political subdivision thereof.

 

“Pro Rata Share” means,
with respect to any Investor, the percentage obtained by dividing (i) the amount of the Advance advanced by such Investor, by (ii)
the aggregate amount of the Advance advanced by the Investors.

 

    	A-7

    	 

    

 

“Second Milestone” means,
with respect to any action that satisfies the definition of “First Milestone”, the entry by a court of a F.R.C.P. 16(b)(1)
scheduling order, after the resolution of any F.R.C.P. 12(b) motions.

 

“Second Milestone Closing Date”
means the date upon which the conditions set forth in Section 5.3 have been satisfied.

 

“Secured Parties” means,
collectively, the Collateral Agent and the Investors.

 

“Security Agreement”
means the Security Agreement attached hereto as Exhibit D.

 

“Securities Act” means
the Securities Act of 1933, as amended.

 

“Solvent” means, with
respect to any Person as of any date of determination, that, as of such date, (a) the value of the assets of such Person (both
at fair value and present fair saleable value) is greater than the total amount of liabilities (including contingent and unliquidated
liabilities) of such Person, (b) such Person is able to pay all liabilities of such Person as such liabilities mature and (c) such
Person does not have unreasonably small capital. In computing the amount of contingent or unliquidated liabilities at any time,
such liabilities shall be computed at the amount that, in light of all the facts and circumstances existing at such time, represents
the amount that can reasonably be expected to become an actual or matured liability.

 

“Subsidiary” means any
other Person of which a specified Person shall at the time, directly or indirectly through one or more of its Subsidiaries, (a)
own at least 50% of the outstanding capital stock (or other shares of beneficial interest) entitled to vote generally, (b) hold
at least 50% of the partnership, joint venture or similar interests or (c) be a general partner or joint venturer.

 

“Synthetic Lease” means
a lease that is treated as an operating lease under GAAP and as a loan or other financing for federal income tax purposes.

 

“Synthetic Lease Obligations”
means the aggregate amount of future rental payments under all Synthetic Leases, discounted as if such Synthetic Leases were Capitalized
Leases.

 

“USA Patriot Act” means
the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001,
Public Law 107-56.

 

    	A-8Execution Version

 

SECURITY AGREEMENT

 

SECURITY AGREEMENT,
dated as of February 13, 2014 (this “Agreement”), by and among DSS Technology Management, Inc., a Delaware Corporation,
(“Grantor”), and Fortress Credit Co LLC, as collateral agent for the Secured Parties (as defined in the Investment
Agreement, as defined below) (in such capacity as collateral agent, the “Collateral Agent”).

 

RECITALS:

 

WHEREAS, reference
is made to that certain Investment Agreement, dated as of the date hereof (as it may be amended, restated, supplemented or otherwise
modified from time to time, the “Investment Agreement”), by and among the Grantor, Document Security Systems,
Inc., the Investors party thereto from time to time and the Collateral Agent; and

 

WHEREAS, in consideration
of the Investors making the Advances as set forth in the Investment Agreement, Grantor has agreed to secure Grantor’s obligations
under the Investment Documents as set forth herein;

 

NOW, THEREFORE, in
consideration of the premises, agreements, provisions and covenants herein contained, and other good and valuable consideration,
the receipt, sufficiency and adequacy of which are hereby acknowledged, Grantor and the Collateral Agent agree as follows:

 

SECTION
1.   DEFINITIONS.

 

1.1.    General
Definitions. In this Agreement, the following terms shall have the following meanings:

 

“Collateral
Support” shall mean all property assigned, hypothecated or otherwise securing any Collateral and shall include any security
agreement or other agreement granting a lien or security interest in such property.

 

“Commercial
Tort Claims” shall mean all “commercial tort claims” as defined in Article 9 of the UCC that relate
to the Patents or rights deriving from the Patents, including, without limitation, all commercial tort claims listed on Schedule
4.3 (as such schedule may be amended or supplemented from time to time).

 

“Investment
Documents” shall have the meaning assigned to the term “Documents” in the Investment Agreement.

 

“Patents” means the letters
patent of the United States set forth on Schedule 4.2, including all registrations and recordings thereof, all applications
for letters patent of the United States or any other jurisdiction, all re-examination certificates and all utility models, including
registrations, recordings and pending applications, and all reissues, continuations, divisions, continuations-in-part, renewals
or extensions thereof, and the inventions claimed therein.

 

    	 

    	 

    

 

“Proceeds”
shall mean: (i) all “proceeds” as defined in Article 9 of the UCC and (ii) whatever is receivable or received
when Collateral or proceeds are sold, exchanged, collected or otherwise disposed of, whether such disposition is voluntary or involuntary.

 

“Security Agreement Supplement”
shall mean any supplement to this agreement in substantially the form of Exhibit A.

 

“Supporting
Obligation” shall mean all “supporting obligations” as defined in Article 9 of the UCC.

 

“UCC”
means the Uniform Commercial Code as in effect from time to time in the Sate of New York; provided that, if perfection or
the effect of perfection or non-perfection or the priority of the security interest in any Collateral is governed by the Uniform
Commercial Code as in effect in a jurisdiction other than the State of New York, “UCC” means the Uniform Commercial
Code as in effect from time to time in such other jurisdiction for purposes of the provisions hereof relating to such perfection,
effect of perfection or non-perfection or priority. 

 

“United States”
shall mean the United States of America.

 

1.2.          Definitions;
Interpretation. All capitalized terms used herein (including the preamble and recitals hereto) but not otherwise defined herein
shall have the respective meanings ascribed to such terms in the Investment Agreement or, if not defined therein, in the UCC. References
to “Sections,” “Exhibits” and “Schedules” shall be to sections, exhibits and schedules, as
the case may be, of this Agreement unless otherwise specifically provided. The rules of construction specified in Section 1.2
of the Investment Agreement also apply to this Agreement.

 

SECTION
2.          GRANT OF SECURITY.

 

2.1.          Grant
of Security. As security for the payment and performance in full of all of the Secured Obligations (as defined in Section
3.1), Grantor hereby grants to Collateral Agent, for the benefit of Secured Parties, a security interest and continuing lien
on all of Grantor’s right, title and interest in, to and under any of the following assets or properties of Grantor, in each
case whether now owned or existing or hereafter acquired or arising and wherever located (all of which are hereinafter collectively
referred to as the “Collateral”):

 

(a)          the
Patents;

 

(b)          all
license agreements relating to the Patents;

 

(c)          Commercial
Tort Claims described on Schedule 4.3 (as such schedule may be amended or supplemented from time to time);

 

(d)          to
the extent not otherwise included above, all Collateral Support and Supporting Obligations relating to any of the foregoing; and

 

(e)          to
the extent not otherwise included above, all Proceeds, products, accessions, rents and profits of or in respect of any of the foregoing.

 

    	2

    	 

    

 

SECTION
3.      SECURITY FOR OBLIGATIONS; GRANTORS REMAIN LIABLE.

 

3.1.       Security
for Obligations. This Agreement secures, and the Collateral is collateral security for, the prompt and complete payment or
performance in full when due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise
(including the payment of amounts that would become due but for the operation of the automatic stay under Section 362(a) of the
Bankruptcy Code, 11 U.S.C. § 362(a) (and any successor provision thereof)), of all Obligations with respect to every
Grantor, whether now existing or hereafter incurred (collectively, the “Secured Obligations”).

 

3.2.       Continuing
Liability Under Collateral. Notwithstanding anything herein to the contrary, (i) Grantor shall remain liable for all obligations
under the Collateral and nothing contained herein is intended to or shall be a delegation of duties to Collateral Agent or any
other Secured Party, (ii) Grantor shall remain liable under each of the agreements included in the Collateral and neither Collateral
Agent nor any other Secured Party shall have any obligation or liability under any of such agreements by reason of or arising out
of this Agreement and (iii) the exercise by Collateral Agent of any of its rights hereunder shall not release Grantor from any
of its duties or obligations under the contracts and agreements included in the Collateral.

 

SECTION
4.        REPRESENTATIONS AND WARRANTIES AND COVENANTS.

 

4.1.          Generally.

 

(a)          Representations
and Warranties. Each Grantor hereby represents and warrants to Collateral Agent and each other Secured Party, as of the Initial
Closing Date, First Milestone Closing Date and Second Milestone Closing Date, that:

 

(i)          it
owns the Collateral purported to be owned by it or otherwise has the rights it purports to have in each item of Collateral and,
as to all Collateral whether now existing or hereafter acquired, will continue to own or have such rights in each item of the Collateral,
in each case free and clear of any and all Liens, rights or claims of all other Persons other than Permitted Liens and other than
the licenses set forth on Schedule 4.1(a);

 

(ii)         it
has indicated on Schedule 4.1(b) (as such schedule may be amended or supplemented from time to time): (w) the type of organization
of Grantor, (x) the jurisdiction of organization of Grantor, (y) its organizational identification number, if any, and (z) the
jurisdiction where the chief executive office or its sole place of business is, and for the one-year period preceding the date
hereof has been, located.

 

(iii)        the
full legal name of Grantor is as set forth on Schedule 4.1(c) and it has not done in the last five (5) years, and does not
do, business under any other name (including any trade-name or fictitious business name) except for those names set forth on Schedule
4.1(c) (as such schedule may be amended or supplemented from time to time);

 

    	3

    	 

    

 

(iv)         except
as provided on Schedule 4.1(c), it has not changed its name, jurisdiction of organization, chief executive office or sole
place of business or its corporate structure in any way (e.g., by merger, consolidation, change in corporate form or otherwise)
within the past five (5) years;

 

(v)          it
has not become bound (whether as a result of merger or otherwise) as debtor under a security agreement entered into by another
Person, which has not heretofore been terminated other than the agreements identified on Schedule 4.1(d) (as such schedule
may be amended or supplemented from time to time);

 

(vi)         (x)
upon the filing of all UCC financing statements naming Grantor as “debtor” and Collateral Agent as “secured party”
and describing the Collateral in the filing offices set forth opposite Grantor’s name on Schedule 4.1(e) (as such
schedule may be amended or supplemented from time to time) and other filings delivered by Grantor and (y) to the extent perfection
or priority of a security interest therein not subject to Article 9 of the UCC, upon recordation of the security interests
granted hereunder in Patents in the applicable intellectual property registries, including but not limited to the United States
Patent and Trademark Office, the security interests granted to Collateral Agent hereunder shall constitute valid and perfected
first priority Liens (subject in the case of priority only to Permitted Liens) on such Collateral;

 

(vii)        all
actions and consents, including all filings, notices, registrations and recordings necessary or desirable for the exercise by Collateral
Agent of the rights provided for in this Agreement or the exercise of remedies in respect of the Collateral have been made or obtained;

 

(viii)      other
than the financing statements filed in favor of Collateral Agent, no effective UCC financing statement, fixture filing or other
instrument similar in effect under any applicable law covering all or any part of the Collateral is on file in any filing or recording
office except for (A) financing statements for which proper termination statements have been delivered to Collateral Agent for
filing and (B) financing statements filed in connection with Permitted Liens; and

 

(ix)         no
authorization, approval or other action by, and no notice to or filing with, any Governmental Authority or regulatory body is required
for either (i) the pledge or grant by Grantor of the Liens purported to be created in favor of Collateral Agent hereunder
or (ii) the exercise by Collateral Agent of any rights or remedies in respect of any Collateral (whether specifically granted or
created hereunder or created or provided for by applicable law), except for the filings contemplated by clause (vi) above.

 

(b)          Covenants
and Agreements. Each Grantor hereby covenants and agrees with Collateral Agent and each other Secured Party that:

 

    	4

    	 

    

 

(i)          it
shall not change Grantor’s name, identity, corporate structure (e.g., by merger, consolidation, change in corporate form
or otherwise) sole place of business, chief executive office, type of organization or jurisdiction of organization or establish
any trade names unless it shall have (A) notified Collateral Agent in writing, by executing and delivering to Collateral Agent
a completed Security Agreement Supplement, together with all Supplements to Schedules thereto, at least fifteen (15) Business Days
prior to any such change or establishment, identifying such new proposed name, identity, corporate structure, sole place of business,
chief executive office, jurisdiction of organization or trade name and providing such other information in connection therewith
as Collateral Agent may reasonably request and (B) taken all actions necessary or advisable to maintain the continuous validity,
perfection and the same or better priority of Collateral Agent’s security interest in the Collateral intended to be granted
and agreed to hereby; and

 

(ii)         it
shall not take or permit any action which could impair Collateral Agent’s rights in the Collateral.

 

4.2.          Intellectual
Property.

 

(a)          Representations
and Warranties. Except as disclosed in Schedule 4.2 (as such schedule may be amended or supplemented from time to time),
Grantor hereby represents and warrants to Collateral Agent and each other Secured Party, as of the Initial Closing Date, First
Milestone Closing Date and Second Milestone Closing Date, that:

 

(i)          it
is the sole and exclusive owner of the entire right, title, and interest in and to all Patents listed on Schedule 4.2, free
and clear of all Liens, claims, encumbrances and licenses, except for Permitted Liens and the licenses set forth on Schedule
2.1 or Schedule 4.2 (as such schedules be amended or supplemented from time to time and, in any event, within 10 days
after a Grantor obtains knowledge of such additional Liens, claims, encumbrances and licenses); and

 

(ii)         all
registrations and applications for Patents of Grantor are standing in the name of Grantor, and none of such Patents has been licensed
by Grantor to any Affiliate or third party, except as disclosed in Schedule 2.1 (as such schedule may be amended or supplemented
from time to time and, in any event, within 10 days after a Grantor obtains knowledge of such additional license).

 

4.3.          Commercial
Tort Claims.

 

(a)          Representations
and Warranties. Each Grantor hereby represents and warrants to Collateral Agent and each other Secured Party, as of the Initial
Closing Date, First Milestone Closing Date and Second Milestone Closing Date, that Schedule 4.3 (as such schedule may be
amended or supplemented from time to time) sets forth all Commercial Tort Claims of Grantor.

 

    	5

    	 

    

 

 

(b)          Covenants
and Agreements. Each Grantor hereby covenants and agrees with Collateral Agent and each other Secured Party that prior to the
initiation of any Commercial Tort Claim hereafter arising it shall deliver to the Collateral Agent a completed Security Agreement
Supplement, together with all Supplements to Schedules thereto, identifying such new Commercial Tort Claims and granting a security
interest therein to the Collateral Agent.

 

SECTION
5.        FURTHER ASSURANCES.

 

5.1.          Further
Assurances.

 

(a)          Each
Grantor agrees that from time to time, at the expense of Grantor, it shall promptly execute and deliver all further instruments
and documents, and take all further action, that may be necessary or desirable, or that Collateral Agent may reasonably request,
in order to create and/or maintain the validity, perfection or priority of and protect any security interest granted or purported
to be granted hereby or to enable Collateral Agent to exercise and enforce its rights and remedies hereunder with respect to any
Collateral. Without limiting the generality of the foregoing, Grantor shall:

 

(i)          file
or authorize the filing of such financing or continuation statements, or amendments thereto, and execute and deliver such other
agreements, instruments, endorsements, powers of attorney or notices, as may be necessary or desirable, or as Collateral Agent
may reasonably request, in order to perfect and preserve the security interests granted or purported to be granted hereby;

 

(ii)         take
all actions necessary to ensure the recordation of appropriate evidence of the liens and security interest granted hereunder in
the Patents with any intellectual property registry in which said Patents are registered or in which an application for registration
is pending including, without limitation, the United States Patent and Trademark Office, the various Secretaries of State, and
the foreign counterparts of any of the foregoing; and

 

(iii)        at
Collateral Agent’s reasonable request, appear in and defend any action or proceeding that may affect Grantor’s title
to or Collateral Agent’s security interest in all or any part of the Collateral.

 

(b)          Each
Grantor hereby authorizes Collateral Agent to file a Record or Records, including, without limitation, financing or continuation
statements, and amendments thereto, in any jurisdictions and with any filing offices as Collateral Agent may determine, in its
sole discretion, are necessary to perfect the security interest granted to Collateral Agent herein. Each Grantor shall furnish
to Collateral Agent from time to time statements and schedules further identifying and describing the Collateral and such other
reports in connection with the Collateral as Collateral Agent may reasonably request, all in reasonable detail.

 

    	6

    	 

    

 

SECTION
6.        COLLATERAL AGENT APPOINTED ATTORNEY-IN-FACT.

 

6.1.          Power
of Attorney. Each Grantor hereby irrevocably appoints Collateral Agent (such appointment being coupled with an interest) as
Grantor’s attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, Collateral
Agent or otherwise, from time to time in Collateral Agent’s discretion to take any action and to execute any instrument that
Collateral Agent may deem reasonably necessary or advisable to accomplish the purposes of this Agreement, including, without limitation,
the following:

 

(a)          upon
the occurrence and during the continuance of any Event of Default (after the expiration of any cure periods as set forth in the
Investment Agreement), to ask for, demand, collect, sue for, recover, compound, receive and give acquittance and receipts for moneys
due and to become due under or in respect of any of the Collateral;

 

(b)          upon
the occurrence and during the continuance of any Event of Default (after the expiration of any cure periods as set forth in the
Investment Agreement), to receive, endorse and collect any drafts or other instruments, documents and chattel paper in connection
with clause (a) above;

 

(c)          upon
the occurrence and during the continuance of any Event of Default (after the expiration of any cure periods as set forth in the
Investment Agreement), to file any claims or take any action or institute any proceedings that Collateral Agent may deem necessary
or desirable for the collection of any of the Collateral or otherwise to enforce the rights of Collateral Agent with respect to
any of the Collateral;

 

(d)          to
prepare and file any UCC financing statements and continuations and amendments thereof against Grantor as debtor;

 

(e)          to
prepare, sign, and file for recordation in any intellectual property registry, appropriate evidence of the lien and security interest
granted herein in the Patents in the name of Grantor as assignor or debtor;

 

(f)          to
take or cause to be taken all actions necessary to perform or comply or cause performance or compliance with the terms of this
Agreement, including, without limitation, access to pay or discharge taxes or Liens (other than Permitted Liens) levied or placed
upon or threatened against the Collateral, the legality or validity thereof and the amounts necessary to discharge the same to
be determined by Collateral Agent in its sole discretion, any such payments made by Collateral Agent to become obligations of Grantor
to Collateral Agent, due and payable immediately without demand; and

 

(g)          upon
the occurrence and during the continuation of an Event of Default (after the expiration of any cure periods as set forth in the
Investment Agreement), generally to sell, transfer, pledge, make any agreement with respect to or otherwise deal with any of the
Collateral as fully and completely as though Collateral Agent were the absolute owner thereof for all purposes, and to do, at Collateral
Agent’s option and Grantor’s expense, at any time or from time to time, all acts and things that Collateral Agent deems
reasonably necessary to protect, preserve or realize upon the Collateral and Collateral Agent’s security interest therein
in order to effect the intent of this Agreement, all as fully and effectively as Grantor might do.

 

    	7

    	 

    

 

6.2.          No
Duty on the Part of Collateral Agent or Secured Parties. The powers conferred on Collateral Agent hereunder are solely to protect
the interests of the Secured Parties in the Collateral and shall not impose any duty upon Collateral Agent or any Secured Party
to exercise any such powers. Collateral Agent and the Secured Parties shall be accountable only for amounts that they actually
receive as a result of the exercise of such powers, and neither they nor any of their respective officers, directors, employees
or agents shall be responsible to Grantor for any act or failure to act hereunder, except for their own gross negligence or willful
misconduct as determined by a final, non-appealable judgment of a court of competent jurisdiction.

 

SECTION
7.         REMEDIES.

 

7.1.          Generally.

 

(a)          If
any Event of Default shall have occurred and be continuing (after the expiration of any cure periods as set forth in the Investment
Agreement), Collateral Agent may exercise in respect of the Collateral, in addition to all the other rights and remedies provided
for herein or in the Investment Agreement, all the rights and remedies of Collateral Agent on default under the UCC (whether or
not the UCC applies to the affected Collateral) to collect, enforce or satisfy any Secured Obligations then owing, whether by acceleration
or otherwise, and also may, without notice except as required under the UCC, exercise its rights under Section 8.2.1.1 through
8.2.1.5 of the Investment Agreement and sell, assign, lease, license (on an exclusive or nonexclusive basis) or otherwise
dispose of the Collateral or any part thereof in one or more parcels at public or private sale, at any of Collateral Agent’s
offices or elsewhere, for cash, on credit or for future delivery, at such time or times and at such price or prices and upon such
other terms as Collateral Agent may deem commercially reasonable.

 

(b)          If
any Event of Default shall have occurred and be continuing (after the expiration of any cure periods as set forth in the Investment
Agreement), the Majority Investors shall have the right to direct Grantor to assign the Patents to a special purpose entity controlled
solely by the Majority Investors, subject to a perpetual, non-transferable, non-exclusive, worldwide, royalty-free license back
to Grantor (without the right to sub-license) that permits Grantor to use the Patents to sell their products and to comply with
its existing contractual obligations under any license listed on Schedule 4.2(a) or other arrangements entered into subsequent
to the Closing Date in compliance with the Investment Agreement. In such event, Grantor’s sole right and interest in such
special purpose vehicle shall be to retain any Monetization Payments (after payment of expenses of the vehicle, including expenses
in pursuing monetization activities related to the Patents) net of the mandatory prepayment of the Obligations pursuant to Section
4.1 or Section 4.2 of the Investment Agreement, which shall be distributed by the special purpose vehicle to the Investors.

 

    	8

    	 

    

 

(c)          Collateral
Agent or any other Secured Party may be the purchaser of any or all of the Collateral at any public or private (to the extent that
the portion of the Collateral being privately sold is of a kind that is customarily sold on a recognized market or the subject
of widely distributed standard price quotations) sale in accordance with the UCC and Collateral Agent, as collateral agent for
and representative of the Secured Parties, shall be entitled, for the purpose of bidding and making settlement or payment of the
purchase price for all or any portion of the Collateral sold at any such sale made in accordance with the UCC, to use and apply
any of the Secured Obligations as a credit on account of the purchase price for any Collateral payable by Collateral Agent at such
sale. Each purchaser at any such sale shall hold the property sold absolutely free from any claim or right on the part of Grantor,
and Grantor hereby waives (to the extent permitted by applicable law) all rights of redemption, stay and/or appraisal which it
now has or may at any time in the future have under any rule of law or statute now existing or hereafter enacted. Each Grantor
agrees that, to the extent notice of sale shall be required by law, at least ten (10) days notice to Grantor of the time and place
of any public sale or the time after which any private sale is to be made shall constitute reasonable notification. Collateral
Agent shall not be obligated to make any sale of Collateral regardless of notice of sale having been given. Collateral Agent may
adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such sale may, without
further notice, be made at the time and place to which it was so adjourned. Each Grantor agrees that it would not be commercially
unreasonable for Collateral Agent to dispose of the Collateral or any portion thereof by using Internet sites that provide for
the auction of assets of the types included in the Collateral or that have the reasonable capability of doing so, or that match
buyers and sellers of assets. Each Grantor hereby waives any claims against Collateral Agent arising by reason of the fact that
the price at which any Collateral may have been sold at such a private sale was less than the price which might have been obtained
at a public sale, even if Collateral Agent accepts the first offer received and does not offer such Collateral to more than one
offeree. If the proceeds of any sale or other disposition of the Collateral are insufficient to pay all the Secured Obligations,
Grantors shall be liable for the deficiency and the fees of any attorneys employed by Collateral Agent to collect such deficiency.
Each Grantor further agrees that a breach of any of the covenants contained in this Section will cause irreparable injury to Collateral
Agent, that Collateral Agent has no adequate remedy at law in respect of such breach and, as a consequence, that each and every
covenant contained in this Section shall be specifically enforceable against Grantor, and Grantor hereby waives and agrees not
to assert any defenses against an action for specific performance of such covenants except for a defense that no default has occurred
giving rise to the Secured Obligations becoming due and payable prior to their stated maturities. Nothing in this Section shall
in any way alter the rights of Collateral Agent hereunder.

 

(d)          Collateral
Agent may sell the Collateral without giving any warranties as to the Collateral. Collateral Agent may specifically disclaim or
modify any warranties of title or the like. This procedure will not be considered to adversely affect the commercial reasonableness
of any sale of the Collateral.

 

(e)          Collateral
Agent shall have no obligation to marshal any of the Collateral.

 

7.2.          Application
of Proceeds. All proceeds received by Collateral Agent in respect of any sale, any collection from, or other realization upon
all or any part of the Collateral shall be applied in full or in part by Collateral Agent against the Secured Obligations as follows:

 

(a)          First,
to payment of that portion of the Secured Obligations constituting fees, indemnities, expenses and other amounts (other than pursuant
to Section 4.1 or Section 4.2 of the Investment Agreement, but including (x) attorney costs and other expenses payable
under Section 10.1 of the Investment Agreement, (y) amounts owing in respect of the preservation of Collateral or the security
interest in the Collateral and (z) amounts owing in respect of enforcing the rights of the Secured Parties under the Investment
Documents) payable to the Collateral Agent in its capacity as such or to the Investors;

 

    	9

    	 

    

 

(b)          Second,
to the payment of that portion of the Secured Obligation constituting amounts owed to the Investors in accordance with Section
4.1 and Section 4.2 of the Investment Agreement; and

 

(c)          Last,
the balance, if any, after all the Secured Obligations have been paid in full, to Grantor or as otherwise required by applicable
law.

 

7.3.          Sales
on Credit. If Collateral Agent sells any of the Collateral upon credit, Grantors will be credited only with payments actually
made by the purchaser thereof and received by Collateral Agent and applied to indebtedness of the purchaser thereof. In the event
the purchaser fails to pay for the Collateral, Collateral Agent may resell the Collateral and Grantors shall be credited with proceeds
of the sale.

 

7.4.          Intellectual
Property.

 

(a)          Anything
contained herein to the contrary notwithstanding, upon the occurrence and during the continuation of an Event of Default (after
the expiration of any cure periods as set forth in the Investment Agreement):

 

(i)          Collateral
Agent may exercise its rights under Sections 8.2.1.1 through 8.2.1.5 of the Investment Agreement;

 

(ii)         Collateral
Agent shall have the right (but not the obligation) to bring suit or otherwise commence any action or proceeding in the name of
Grantor, Collateral Agent or otherwise, in Collateral Agent’s sole discretion, to enforce any Patents, in which event Grantor
shall, at the request of Collateral Agent, do any and all lawful acts and execute any and all documents required by Collateral
Agent in aid of such enforcement and Grantor shall promptly, upon demand, reimburse and indemnify Collateral Agent as provided
in Sections 10.1 and 10.2 of the Investment Agreement in connection with the exercise of its rights under this Section,
and, to the extent that Collateral Agent shall elect not to bring suit to enforce any Patents as provided in this Section, Grantor
agrees to use all reasonable measures, whether by action, suit, proceeding or otherwise, to prevent the infringement or other violation
of any of Grantor’s rights in the Patents by any other Person and for that purpose agrees to diligently maintain any action,
suit or proceeding against any Person so infringing as shall be necessary to prevent such infringement or violation;

 

(iii)        upon
written demand from Collateral Agent, Grantor shall grant, assign, convey or otherwise transfer to Collateral Agent or such Collateral
Agent’s designee all of Grantor’s right, title and interest in and to the Patents and shall execute and deliver to
Collateral Agent such documents as are necessary or appropriate to carry out the intent and purposes of this Agreement;

 

(iv)         Grantor
agrees that such an assignment and/or recording shall be applied to reduce the Secured Obligations outstanding only to the extent
that Collateral Agent (or any other Secured Party) receives cash proceeds in respect of the sale of, or other realization upon,
the Patents; and

 

    	10

    	 

    

 

(v)          Collateral
Agent shall have the right to notify, or require Grantor to notify, any obligors with respect to amounts due or to become due to
Grantor in respect of the Patents, of the existence of the security interest created herein, to direct such obligors to make payment
of all such amounts directly to Collateral Agent, and, upon such notification and at the expense of Grantor, to enforce collection
of any such amounts and to adjust, settle or compromise the amount or payment thereof, in the same manner and to the same extent
as Grantor might have done;

 

(1)         all
amounts and proceeds (including checks and other instruments) received by Grantor in respect of amounts due to Grantor in respect
of the Collateral or any portion thereof shall be received in trust for the benefit of Collateral Agent hereunder, shall be segregated
from other funds of Grantor and shall be forthwith paid over or delivered to Collateral Agent in the same form as so received (with
any necessary endorsement) to be held as cash Collateral; and

 

(2)         no
Grantor shall adjust, settle or compromise the amount or payment of any such amount or release wholly or partly any obligor with
respect thereto or allow any credit or discount thereon.

 

(b)          If
(i) an Event of Default shall have occurred and, by reason of cure, waiver, modification, amendment or otherwise, is no longer
continuing, (ii) no other Event of Default shall have occurred and be continuing, (iii) an assignment or other transfer to Collateral
Agent of any rights, title and interests in and to the Patents shall have been previously made and shall have become absolute and
effective, and (iv) the Secured Obligations shall not have become immediately due and payable, upon the written request of Grantor,
Collateral Agent shall promptly execute and deliver to Grantor, at Grantor’s sole cost and expense, such assignments or other
transfer as may be necessary to reassign to Grantor any and all such rights, title and interests as may have been assigned to Collateral
Agent as aforesaid, subject to any disposition thereof that may have been made by Collateral Agent; provided, after giving
effect to such reassignment, Collateral Agent’s security interest granted pursuant hereto, as well as all other rights and
remedies of Collateral Agent granted hereunder, shall continue to be in full force and effect; and provided further,
the rights, title and interests so reassigned shall be free and clear of any other Liens granted by or on behalf of Collateral
Agent and the Secured Parties.

 

    	11

    	 

    

 

SECTION
8.        COLLATERAL AGENT.

 

Collateral Agent has
been appointed to act as “Collateral Agent” hereunder by Investors pursuant to the Investment Agreement. Collateral
Agent shall be obligated, and shall have the right hereunder, to make demands, to give notices, to exercise or refrain from exercising
any rights, and to take or refrain from taking any action (including, without limitation, the release or substitution of Collateral),
solely in accordance with this Agreement and the other Investment Documents; provided, Collateral Agent shall, after payment
in full of all Obligations under the Investment Agreement and the other Investment Documents, exercise, or refrain from exercising,
any remedies provided for herein in accordance with the instructions of the Majority Investors. In furtherance of the foregoing
provisions of this section, each Secured Party, by its acceptance of the benefits hereof, agrees that it shall have no right individually
to realize upon any of the Collateral hereunder, it being understood and agreed by such Secured Party that all powers, rights and
remedies hereunder may be exercised solely by Collateral Agent for the benefit of Secured Parties in accordance with the terms
of this section. Collateral Agent may resign, and a successor be appointed, in accordance with the Investment Agreement. After
any retiring Collateral Agent’s resignation hereunder as Collateral Agent, the provisions of this Agreement shall inure to
its benefit as to any actions taken or omitted to be taken by it under this Agreement while it was Collateral Agent hereunder.

 

SECTION
9.    CONTINUING SECURITY INTEREST; TRANSFER OF RIGHTS UNDER INVESTMENT DOCUMENTS.

 

This Agreement shall
create a continuing security interest in the Collateral and shall remain in full force and effect until the payment in full of
all Secured Obligations, be binding upon Grantor, its successors and assigns, and inure, together with the rights and remedies
of Collateral Agent hereunder, to the benefit of Collateral Agent and its successors, transferees and assigns. Without limiting
the generality of the foregoing, but subject to the terms of the Investment Agreement, any Investor may assign or otherwise transfer
any rights held by it under the Investment Documents to any other Person, and such other Person shall thereupon become vested with
all the benefits in respect thereof granted to Investors herein or otherwise. Upon the payment in full of all Secured Obligations,
the security interest granted hereby shall automatically terminate hereunder and of record and all rights to the Collateral shall
revert to Grantors. Upon any such termination, Collateral Agent shall, at Grantors’ expense, execute and deliver to Grantors
or otherwise authorize the filing of such release documents as Grantors shall reasonably request, including financing statement
amendments to evidence such termination, in each case, such documents to be in form and substance satisfactory to Collateral Agent
and without representation or warranty by, or recourse to, Collateral Agent. Upon any disposition of property permitted by the
Investment Agreement, the Liens granted herein shall be deemed to be automatically released and such property shall automatically
revert to the applicable Grantor with no further action on the part of any Person. Collateral Agent shall, at Grantor’s expense,
execute and deliver or otherwise authorize the filing of such documents as Grantors shall reasonably request, in form and substance
reasonably satisfactory to Collateral Agent and without representation or warranty by, or recourse to, Collateral Agent, including
financing statement amendments to evidence such release.

 

SECTION
10.           STANDARD OF CARE; COLLATERAL AGENT MAY PERFORM.

 

The powers conferred
on Collateral Agent hereunder are solely to protect its interest in the Collateral and shall not impose any duty upon it to exercise
any such powers. Except for the exercise of reasonable care in the custody of any Collateral in its possession and the accounting
for moneys actually received by it hereunder, Collateral Agent shall have no duty as to any Collateral or as to the taking of any
necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral. Collateral Agent shall
be deemed to have exercised reasonable care in the custody and preservation of Collateral in its possession if such Collateral
is accorded treatment substantially equal to that which Collateral Agent accords its own property. Neither Collateral Agent nor
any of its directors, officers, employees or agents shall be liable for failure to demand, collect or realize upon all or any part
of the Collateral or for any delay in doing so or shall be under any obligation to sell or otherwise dispose of any Collateral
upon the request of Grantor or otherwise. If Grantor fails to perform any agreement contained herein, Collateral Agent may itself
perform, or cause performance of, such agreement, and the expenses of Collateral Agent incurred in connection therewith shall be
payable by Grantor under Section 10.1 of the Investment Agreement.

 

    	12

    	 

    

 

SECTION
11.          INDEMNITY

 

The Grantors (as “Indemnitor”)
agree to indemnify, pay and hold the Secured Parties, and the officers, directors, partners, managers, members, employees, agents,
and Affiliates of the Secured Parties (collectively, the “Indemnitees”) harmless from and against any and all
other liabilities, costs, expenses, obligations, losses (other than lost profit), damages, penalties, actions, judgments, suits,
claims and disbursements of any kind or nature whatsoever (including, without limitation, the reasonable fees and disbursements
of one counsel for such Indemnitees) in connection with any investigative, administrative or judicial proceeding commenced or threatened
by a third party (excluding claims among Indemnitees), whether or not such Indemnitee shall be designated a party thereto, which
may be imposed on, incurred by, or asserted against that Indemnitee by a third party, in any manner relating to or arising out
of this Agreement (the “Indemnified Liabilities”); provided that the Indemnitor shall not have any obligation
to an Indemnitee hereunder with respect to an Indemnified Liability to the extent that such Indemnified Liability arises from the
gross negligence or willful misconduct of that Indemnitee or any of its officers, directors, partners, managers, members, employees,
agents and/or Affiliates. Each Indemnitee shall give the Indemnitor prompt written notice of any claim that might give rise to
Indemnified Liabilities setting forth a description of those elements of such claim of which such Indemnitee has knowledge; provided
that any failure to give such notice shall not affect the obligations of the Indemnitor. The Indemnitor shall have the right at
any time during which such claim is pending to select counsel to defend and control the defense thereof and settle any claims for
which it is responsible for indemnification hereunder (provided that the Indemnitor will not settle any such claim without
(i) the appropriate Indemnitee’s prior written consent, which consent shall not be unreasonably withheld or (ii) obtaining
an unconditional release of the appropriate Indemnitee from all claims arising out of or in any way relating to the circumstances
involving such claim and without any admission as to culpability or fault of such Indemnitee) so long as in any such event, the
Indemnitor shall have stated in a writing delivered to the Indemnitee that, as between the Indemnitor and the Indemnitee, the Indemnitor
is responsible to the Indemnitee with respect to such claim to the extent and subject to the limitations set forth herein; provided
that the Indemnitor shall not be entitled to control the defense of any claim in the event that in the reasonable opinion of counsel
for the Indemnitee, there are one or more material defenses available to the Indemnitee which are not available to the Indemnitor;
provided further, that with respect to any claim as to which the Indemnitee is controlling the defense, the Indemnitor will
not be liable to any Indemnitee for any settlement of any claim pursuant to this Section 11 that is effected without
its prior written consent, which consent shall not be unreasonably withheld. To the extent that the undertaking to indemnify, pay
and hold harmless set forth in this Section 11 may be unenforceable because it is violative of any law or public policy,
Grantor shall contribute the maximum portion which it is permitted to pay and satisfy under applicable law, to the payment and
satisfaction of all Indemnified Liabilities incurred by the Indemnitees or any of them.

 

    	13

    	 

    

 

SECTION
12.          MISCELLANEOUS.

 

Any notice required
or permitted to be given under this Agreement shall be given in accordance with Section 10.3 of the Investment Agreement.
No failure or delay on the part of Collateral Agent in the exercise of any power, right or privilege hereunder or under any other
Investment Document shall impair such power, right or privilege or be construed to be a waiver of any default or acquiescence therein,
nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of
any other power, right or privilege. All rights and remedies existing under this Agreement and the other Investment Documents are
cumulative to, and not exclusive of, any rights or remedies otherwise available. In case any provision in or obligation under this
Agreement shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining
provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired
thereby. All covenants hereunder shall be given independent effect so that if a particular action or condition is not permitted
by any of such covenants, the fact that it would be permitted by an exception to, or would otherwise be within the limitations
of, another covenant shall not avoid the occurrence of a Default or an Event of Default if such action is taken or condition exists.
This Agreement shall be binding upon and inure to the benefit of Collateral Agent and Grantors and their respective successors
and assigns. No Grantor shall, without the prior written consent of Collateral Agent given in accordance with the Investment Agreement,
assign any right, duty or obligation hereunder. This Agreement and the other Investment Documents embody the entire agreement and
understanding between Grantors and Collateral Agent and supersede all prior agreements and understandings between such parties
relating to the subject matter hereof and thereof. Accordingly, the Investment Documents may not be contradicted by evidence of
prior, contemporaneous or subsequent oral agreements of the parties. There are no unwritten oral agreements between the parties.
This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which
when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the
same instrument; signature pages may be detached from multiple separate counterparts and attached to a single counterpart so that
all signature pages are physically attached to the same document. Delivery of an executed counterpart of a signature page of this
Agreement by facsimile or other electronic transmission shall be effective as a manually executed counterpart of this Agreement.
In an event of a conflict between the terms and conditions of this Agreement and the terms and conditions of the Investment Agreement,
the terms and conditions of the Investment Agreement shall control.

 

THIS AGREEMENT AND
THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH,
THE LAWS OF THE STATE OF NEW YORK, EXCEPT TO THE EXTENT THAT THE VALIDITY OR PERFECTION OF THE SECURITY INTEREST OR THE REMEDIES
HEREUNDER IN RESPECT OF ANY COLLATERAL ARE GOVERNED BY THE LAW OF A JURISDICTION OTHER THAN THE STATE OF NEW YORK.

 

    	14

    	 

    

 

TO THE EXTENT NOT
PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, EACH PARTY HERETO WAIVES, AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS
PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY FORUM IN RESPECT OF ANY ISSUE, CLAIM OR PROCEEDING ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE CONDUCT OF THE PARTIES HERETO, WHETHER NOW EXISTING OR HEREAFTER ARISING AND WHETHER
IN CONTRACT, TORT OR OTHERWISE.  The Grantors acknowledge that they have been informed by the Secured Parties that the foregoing
sentence constitutes a material inducement upon which the Secured Parties have relied and will rely in entering into this Agreement.
Grantor or the Secured Parties may file an original counterpart or a copy of this Agreement with any court as written evidence
of the consent of the Grantor and the Secured Parties to the waiver of their rights to trial by jury.

 

Each party hereto (a)
irrevocably submits to the exclusive jurisdiction of any New York state court or federal court sitting in New York, New York, and
any court having jurisdiction over appeals of matters heard in such courts, for the purpose of any suit, action or other proceeding
arising out of or based upon this Agreement or the subject matter hereof or thereof; (b) waives to the extent not prohibited by
applicable law that cannot be waived, and agrees not to assert, by way of motion, as a defense or otherwise, in any such proceeding
brought in any of the above-named courts, any claim that they are not subject personally to the jurisdiction of such court, that
their property is exempt or immune from attachment or execution, that such proceeding is brought in an inconvenient forum, that
the venue of such proceeding is improper, or that this Agreement, or the subject matter hereof or thereof, may not be enforced
in or by such court; (c) consents to service of process in any such proceeding in any manner at the time permitted under the applicable
laws of the State of New York and agree that service of process by registered or certified mail, return receipt requested, at the
address specified in or pursuant to Section 10.3 of the Investment Agreement is reasonably calculated to give actual notice;
and (d) waives to the extent not prohibited by applicable law that cannot be waived any right to claim or recover in any such proceeding
any special, exemplary, punitive or consequential damages.

 

[Remainder of Page Intentionally Blank]

 

    	15

    	 

    

 

IN WITNESS WHEREOF,
Grantor and Collateral Agent have caused this Agreement to be duly executed and delivered by their respective officers thereunto
duly authorized as of the date first written above.

 

	 	GRANTOR:	 
	 	 	 	 
	 	DSS Technology Management, Inc.	 
	 	 	 	 
	 	 	/s/ Jeffrey Ronaldi	 
	 	By:	Jeffrey Ronaldi	 
	 	Title:	 Chief Executive Officer	 

 

[Signature Page to Security Agreement]

 

    	 

    	 

    

 

	 	COLLATERAL AGENT:	 
	 	 	 
	 	Fortress Credit Co LLC	 
	 	 	 
	 	By:	/s/ Constantine M. Dakolias	 
	 	 	 	 
	 	Name:	Constantine M. Dakolias	 
	 	 	 	 
	 	Title: 	President	 

 

 

[Signature Page to Security Agreement]

 

    	 

    	 

    

 

EXHIBIT A

TO SECURITY AGREEMENT

 

Security
Agreement SUPPLEMENT

 

This SECURITY AGREEMENT
SUPPLEMENT, dated [mm/dd/yy], is delivered by [NAME OF GRANTOR] a [NAME OF STATE OF INCORPORATION] [Corporation]
(the “Grantor”) pursuant to the Security Agreement, dated as of February 13, 2014 (as it may be from time to
time amended, restated, modified or supplemented, the “Security Agreement”), among DSS Technology Management,
Inc., a Delaware corporation, the other Grantors named therein, and Fortress Credit Co LLC, as the Collateral Agent. Capitalized
terms used herein not otherwise defined herein shall have the meanings ascribed thereto in the Security Agreement.

 

Grantor hereby confirms
the grant to Collateral Agent set forth in the Security Agreement of, and does hereby grant to Collateral Agent, a security interest
in all of Grantor’s right, title and interest in and to all Collateral to secure the Secured Obligations, in each case whether
now or hereafter existing or in which Grantor now has or hereafter acquires an interest and wherever the same may be located and
specifically, without limitation, grants to the Collateral Agent a security interest in all of Grantor’s right, title and
interest in the Commercial Tort Claims referenced on Schedule 4.3. Grantor represents and warrants to Collateral Agent and
each other Secured Party that the attached Supplements1
to Schedules accurately and completely set forth all additional information required pursuant to the Security Agreement and hereby
agrees that such Supplements to Schedules shall constitute part of the Schedules to the Security Agreement.

 

IN WITNESS WHEREOF,
Grantor has caused this Security Agreement Supplement to be duly executed and delivered by its duly authorized officer as of [mm/dd/yy].

 

	 	[NAME OF GRANTOR]	 
	 	 	 	 
	 	By:	 	 
	 	 	Name:	 
	 	 	Title:	 

 

 

1 Supplemental schedules to be
attached

 

    	 

    	 

    

 

Schedule 4.1(a) 

 

The Patents are subject to the license agreements identified
on Exhibit C to that certain Patent Purchase Agreement between the Company and Cypress Semiconductor Corporation, dated
September 23, 2013, which Exhibit C is hereby incorporated by reference.

 

Schedule 4.1(b)

 

DSS Technology Management, Inc.

(w)         Corporation

(x)          Delaware

(y)          Delaware
Secretary of State File No. 5152929

(z)          Virginia

 

Schedule 4.1(c)

 

The full legal name of the Grantor is DSS Technology Management,
Inc.

 

The Grantor has previously been known as SNIP, Inc. and Lexington
Technology Group, Inc.

 

Schedule 4.1(d)

 

Not applicable.

 

Schedule 4.1(e)

 

UCC financing statements to be filed with the Secretary of State
for the State of Delaware.

 

    	 

    	 

    

 

Schedule 4.2    Patents

 

Patent Registrations:

 

	owner	 	registration

number	 	title
	DSS Technology Management, Inc.	 	5,686,223	 	Method for Reduced Pitch Lithography
	DSS Technology Management, Inc.	 	5,652,084	 	Method for Reduced Pitch Lithography
	DSS Technology Management, Inc.	 	5,695,924	 	Metal Plug Local Interconnect
	DSS Technology Management, Inc.	 	5,401,691	 	Method of Fabrication an Inverse Open Frame Alignment Mark
	DSS Technology Management, Inc.	 	6,066,555	 	Method for Eliminating Lateral Spacer Erosion on Enclosed Contact Topographies During RF Sputter Cleaning
	DSS Technology Management, Inc.	 	6,784,552	 	Structure Having Reduced Lateral Spacer Erosion
	DSS Technology Management, Inc.	 	5,503,962	 	Chemical-Mechanical Alignment Mark and Method of Fabrication
	DSS Technology Management, Inc.	 	5,675,178	 	No-Bond Integrated Circuit Inputs
	DSS Technology Management, Inc.	 	5,913,712	 	Scratch Reduction in Semiconductor Circuit Fabrication Using Chemical-Mechanical Polishing

 

Patent Applications:

 

	owner	 	Application

number	 	title
	DSS Technology Management, Inc.	 	08/361,595	 	Method for Reduced Pitch Lithography
	DSS Technology Management, Inc.	 	08/510,717	 	Method for Reduced Pitch Lithography
	DSS Technology Management, Inc.	 	08/561,951	 	Method for Plug Local Interconnect
	DSS Technology Management, Inc.	 	08/512,771	 	Scratch Reduction in Semiconductor Circuit Fabrication Using Chemical-Mechanical Polishing

 

    	 

    	 

    

 

Schedule 4.3 Commercial Tort Claims

 

None.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]